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ABSTRACT 
 
NAMAN KIRIT SHAH: Reducing Malaria Transmission: The Epidemiology and Treatment 
of Plasmodium falciparum Gametocytemia 
(Under the direction of Steven R Meshnick, MD, PhD, and Neena Valecha, MD) 
 
Gametocytes are the sexual stage of the Plasmodia life cycle which render malaria 
cases infectious to mosquitoes. The proportion of P. falciparum malaria cases with 
gametocytemia and the duration of gametocytemia are varied. Interventions for detecting and 
treating gametocytemia also differ from those used against asexual parasitemia. In areas of 
low transmission, such as most of India, the size of the infectious reservoir drives 
transmission. The purpose of this dissertation was to 1) determine the epidemiology and risk 
factors for gametocytemia in order to better target interventions, and 2) estimate the effect of 
primaquine in addition to artesunate plus sulfadoxine-pyrimethamine (AS+SP) to guide 
policy for reducing post-treatment malaria transmission. Using data from therapeutic efficacy 
studies conducted through the National Antimalarial Drug Resistance Monitoring System 
from 2009 to 2010, we measured the prevalence of gametocytemia in relation to various 
clinical and demographic factors. We found that all age groups, including adults, contribute 
substantially to the reservoir for potential transmission. We identified four risk factors – 
younger age group, previous antimalarial drug intake, sex, and region – from which we 
created a clinical algorithm for predicting gametocytemia. The predictive power of the model 
was low, suggesting the need for a universal approach for anti-gametocyte interventions. We 
compared trial sites which used primaquine to sites which did not to estimate the additional 
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effect of primaquine. AS+SP with primaquine increased the rate of gametocyte clearance, 
prevented the development of new gametocytemia, and reduced the area under the 
gametocyte density over time curve over the study follow-up compared to AS+SP alone. 
Primaquine was well tolerated and no serious adverse events were reported. Adding 
primaquine to AS+SP for the treatment of P. falciparum infection in India would decrease 
the potential for post-treatment malaria transmission. 
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 “Now it is to these gametocytes that an extreme interest attaches, 
because it is to them, and to Manson's study of them, that we owe the solution 
of the malaria problem.”  
 
- Sir Ronald Ross (1) 
1900 
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CHAPTER ONE: SPECIFIC AIMS 
 
Gametocytes are the sexual stage of Plasmodia life cycle which render malaria cases 
infectious to mosquitoes and propagate transmission. The proportion of P. falciparum 
malaria cases with gametocytemia and the duration and density of that gametocytemia are 
varied. In areas of low transmission, such as most of India, the number of infective hosts, as 
opposed to vectorial capacity, determines transmission. Thus, studies of the epidemiology of 
gametocytemia are needed to better define this key reservoir. Interventions for detecting and 
treating gametocytemia also differ from those used against asexual parasitemia. So an 
improved understanding of gametocytes opens the possibility of distinct transmission-
blocking control strategies for the nation.  
First, which case-patients carry gametocytes? Universal application of 
gametocytocidal interventions adds cost and may expose some individuals to potentially 
severe side effects. Targeting interventions by direct examination of gametocytes during 
routine microscopy can be difficult due to low density, poor training, and the heavy workload 
of the microscopist. Easily discerned risk factors associated with gametocytemia could help 
but these have not been assessed in Indian transmission settings where, in comparison to sub-
Saharan Africa, natural immunity is low, many patients are adults, and the presence of 
competing malaria species may be an important determinant. Risk factors used in a clinical 
risk score could enable field-level screening.  
 
2 
 
Second, how should we treat gametocytemia? Artemisinin combination therapies 
(ACT), the first-line treatment in most countries including India, eliminate immature 
gametocytes but not mature gametocytes which may persist for up to one month post-
treatment. The key operational question is whether a single dose of primaquine, which is 
inexpensive and effective against mature gametocytes, should be added to artemisinin 
combination therapies to reduce the potential post-treatment transmission of the infection. 
Currently, we have little data regarding the safety or effectiveness of doing so.  
This dissertation aims to describe the epidemiology of gametocytemia in India, 
including its prevalence, age-structure, and risk factors, as well as estimate the effect of 
primaquine in addition to an ACT for improving the control of malaria in the country by 
reducing potential transmission. We used data from the National Antimalarial Drug 
Resistance Monitoring System, run by the National Institute of Malaria Research (NIMR) 
and the National Vector Borne Disease Control Programme (NVBDCP), which conducted 
therapeutic efficacy trials at 21 sentinel sites during 2009 and 2010, where 9 sites used 
primaquine in addition to artesunate plus sulfadoxine-pyrimethamine (AS+SP) while 12 used 
AS+SP alone. 
 
Specific Aim 1  
Determine which P. falciparum patients carry gametocytes. We will compare the 
prevalence of gametocytemia among the clinical and demographic factors available in 
routine settings (i.e. age, gender, asexual parasite density, current fever, previous 
antimalarial drug intake, region, etc.) and develop a risk score for detecting 
gametocytemia  
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Rationale:  
Identifying the type of person likely to carry gametocytes may enable us to target 
individuals for screening and/or treatment without the need for diagnostic equipment. 
Conversely, an inability to target accurately would suggest the need for universal 
application of interventions. 
 
Specific Aim 2 
Estimate the effect of adding primaquine to artemisinin combination therapy on post-
treatment clearance (gametocyte survival) and post-treatment carriage (gametocyte 
incidence) during 28 days of follow-up 
Rationale:  
Measuring the effectiveness of primaquine will provide the first quantitative data on 
the transmission blocking role of primaquine in combination with an ACT in India 
and guide the national drug policy. 
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
MALARIA AS A PUBLIC HEALTH PROBLEM 
Malaria is the resultant febrile illness from an infection by a parasite of the 
Plasmodium genus. Plasmodium ovale, P. malariae, P. vivax, and P. falciparum represent 
the four main species which infect humans (2); the latter two are responsible for the vast 
majority of disease burden and most fatal cases are attributed to P. falciparum which can 
cause severe malaria. Health effects of malaria infection include debilitating illness such as 
severe anemia, jaundice, kidney failure, coma, and death (3). According to the World Health 
Organization, approximately 40 percent of the world is still at risk for malaria (4). An 
estimated 225 million clinical episodes and 0.8 million deaths due to malaria occurred in 
2008 (4). However considerable uncertainty exists around the estimates, particularly fatal 
cases, both globally and applied to individual country levels (5). As with many tropical 
diseases, malaria risk is inequitable with approximately 58% of cases distributed among the 
poorest quintile of the world‟s population (6). Historical declines in malaria have in general 
been maintained only where development was associated with a reduction of the social and 
economic risk factors for the disease (7,8). Despite the existence of successful control 
interventions for over 100 years and the elimination of the disease from large parts of the 
world, malaria remains a grave public health concern. 
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STAGES IN THE MALARIA LIFE CYCLE 
The malaria parasite has a complex life cycle traversing through both mosquito and 
human hosts (Figure 2.1). Within persons there is the liver stage of infection (exo-
erythrocytic) where the infection begins, and in the case of P. vivax and P. ovale dormancy 
may persist, and a blood stage (erythrocytic cycle) which produces clinical symptoms (2). 
Gametocytes are the sexual stage of Plasmodia life cycle which render malaria cases 
infectious to mosquitoes and propagate transmission (9).  
In P. vivax gametocytes appear in most cases and shortly after the emergence of 
asexual parasites from the exo-erythrocytic cycle (10). In P. falciparum however, the 
proportion of malaria cases with gametocytemia and the duration and density of that 
gametocytemia are varied (11). Furthermore, infective gametocytes1 do not appear until later 
in the blood-stage infection nearly several days after patency (the first appearance of 
parasites in the blood stream) and multiple cycles of asexual parasitemia (12). The mean 
duration of survival for a mature gametocyte is between 4-6 days (13,14) (Figure 2.2 A). 
Coupled with the maturation and progressive release of sequestered gametocytes, 
gametocytemia may persist for three to six weeks after the elimination of its precursor 
asexual stages (by successful treatment for example) however the viability of gametocytes 
towards the end of this period, that is their ability to infect mosquitoes, is less certain 
(13,15,16) (Figure 2.2 B).  
 
                                                            
1 From here on gametocyte or gametocytemia refers to those of P. falciparum only 
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EPIDEMIOLOGY OF GAMETOCYTEMIA 
Although gametocytes are central to understanding transmission, few studies in the 
past 50 years have tried to demarcate the infectious reservoir (15). This may be because in 
high transmission areas of interest, namely sub-Saharan Africa which has long dominated the 
donor perspective given its high burden and generally poor health systems, the infectious 
reservoir is not an important determinant of the intensity of transmission relative to high 
vector competence (17). However, in low transmission areas, where the vector is not as 
efficient, the proportion of infectious hosts is more critical to the maintenance of endemicity 
(17). With recent reductions in malaria transmission due to intervention scale-up, and 
increased focus on malaria elimination worldwide, interest in the epidemiology of 
gametocytes is gaining traction with the hopes that a better understand will help reduce the 
remaining infectious reservoir (18–20).   
Microscopically detected gametocytemia is typically present in less than 50% of 
cases (21) though the proportion rises greatly using molecular techniques, albeit at lower 
densities (13). The overall density of gametocytes among the total parasite population tends 
to be low, typically less than 5% of parasites (22,23). A key aspect of gametocyte 
epidemiology is age related trends due to immunity (24). In high transmission settings, the 
proportion of infections with gametocytemia is higher in children (25,26). It is unclear 
whether age directly affects gametocytemia or whether this is just a reflection of the higher 
overall parasite density, which leads to more gametocytemia, which is typically found in 
children (27). However, among individuals with gametocytemia, the density of gametocytes 
relative to total parasite density is higher in adults (28,29). In low transmission settings 
gametocytemia is thought to be more evenly distributed (26,30). There is limited evidence 
for seasonal differences (31–34) in gametocytemia though other factors such as longer 
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duration of clinical symptoms (30,35,36), being afebrile at the time of presentation (37), and 
previous antimalarial drug intake (38), and epidemic situations are associated with a higher 
prevalence of gametocytemia (39,40).  
CONTROL OF GAMETOCYTES  
The control of gametocytes is largely achieved through general malaria control. 
Treatment of parasitemia prevents the generation of new gametocytes and limits infectivity, 
while vector control measures, in addition to protecting individuals from new infections, 
prevents mosquito uptake of existing infections. Gametocyte-specific interventions are, at 
present, limited to its diagnosis and treatment which we discuss in more detail. In the future, 
preventative interventions such as transmission-blocking vaccines, which induce immunity 
against gametocytes or the mosquito stage gamete, may be available (41,42).  
 
DIAGNOSIS OF GAMETOCYTEMIA 
Typically gametocytes are diagnosed through light microscopy using the same 
methods as those for screening parasitemia. P. falciparum gametocytes, with their large 
crescents shape, are distinctive and easy to recognize. The detection limit for thick film 
microscopy of approximately 8-40 parasites per microliter (depending on whether 200-1000 
WBC counted) poses a challenge though as gametocyte density is substantially lower than 
that of asexual parasites (typically <5% of the total population). Thus, microscopy is a 
specific tool but its sensitivity may vary. Coupled with poor training and heavy workloads, 
the diagnosis of gametocytemia in routine settings is difficult.  
Recently, molecular methods that detect gametocyte-stage specific RNA transcripts 
have been employed (43–45). The measured prevalence with molecular tools ranged between 
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2-4 times that detected by microscopy (46–51). However, not all gametocytemia is the same. 
While sub-microscopic density infections can infect mosquitoes, the probability of infection, 
the proportion of mosquitoes infected, and the density of infection in mosquitoes increases 
with increased gametocyte density (48,52). Comparisons of host infectivity must account for 
both the frequency and magnitude of gametocytemia. 
 
TREATMENT OF GAMETOCYTEMIA 
 Most antimalarial drugs target blood-stage schizonts, responsible for clinical 
symptoms, and have varying activity against gametocytes. Chloroquine, quinine, and 
sulfadoxine-pyrimethamine are active against newly differentiated gametocytes but lose 
potency as gametocyte development progresses (53–57). In fact, with some of these drugs 
post-treatment increases in gametocytemia are often observed, attributed to increased “stress” 
acting through some unknown mechanism, inducing gametocytogenesis among remaining 
parasites to ensure survival. Artemisinin is a potent gametocytocidal drug against all stages 
except for those already fully mature (i.e. in peripheral circulation) and this characteristic 
contributed to the impressive declines in transmission following the widespread 
implementation of combination therapy in several countries, notably Thailand (58). 
However, remaining mature gametocytes (present in 10-30% of patients), remain infectious 
and persist for up to a month post-treatment and can therefore contribute to transmission 
(51,59–62).  
Primaquine, which has no activity against asexual P. falciparum parasites, is effective 
against mature gametocytes but its activity against immature gametocytes is less certain (63–
65). A single-dose of primaquine has been used as an as an adjunct treatment alongside first-
line therapies, for its gametocytocidal effect, in many countries since the 1960s (66–70). One 
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challenge with primaquine is the concern over its safety in G6PD deficient patients and 
others where the drug can precipitate mild to severe hemolysis (71–73). However, the safety 
of a single dose, rapidly eliminated, is thought to be greater than the 14 day anti-relapse 
treatment provided in P. vivax treatment which was the principal cause of safety concerns 
(74). The ethics for single-dose primaquine have been questioned in light of these risks and 
the community rather than individual level benefit conferred (74).Studies of artemisinin 
combination therapies (ACT) with primaquine indicate reductions in gametocyte carriage, 
area under the curve, clearance time, and infectivity, whether assessed microscopically or by 
molecular techniques, relative to ACT alone (66–70). The magnitude of the effect appears to 
vary though with reduction in post-treatment gametocyte carriage of 25-75% among African 
children, 60% in Colombian adults, and 92% in Burmese patients of all ages (47,75,76).  
 
MALARIA IN INDIA 
The Republic of India represents the largest national population at risk for malaria in 
the world with 85% of the populace residing in malarious zone (77,78) (Figure 2.3). Both 
major Plasmodium species, six primary malaria vectors, several ecotypes including urban 
malaria, and transmission intensities ranging from unstable to hyper endemic highlight the 
challenging malaria epidemiology in the nation (79). At the time of independence in 1947, 
the Indian people were suffering from an estimated 75 million cases and 800,000 deaths per 
year (80).
 
After independence health care was prioritized and the control of malaria was one 
of the key aims of the Government of India (GoI). In 1953, the National Malaria Control 
Programme (NMCP) was launched under the Ministry of Health and Family Welfare 
(MoHFW) and protected a population of approximately 165 million with DDT spraying (81). 
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The control programme evolved into the National Malaria Eradication Programme (NMEP) 
in 1958 (82). Reliable surveillance gradually developed during the eradication period (83) 
and the programme seemed to be highly effective with only 99,667 malaria cases and zero 
deaths reported in 1965 (84).  
However, the long-term success of malaria control could not be sustained (85). 
Increasing insecticide resistance in mosquitoes, urbanization, population migration, 
integration with the general health services, financial difficulties and other operational 
challenges laid the foundation for a resurgence of malaria (84,86). In 1976, malaria cases 
reached a post-eradication peak of 6.47 million cases (87). A new strategy, the Modified Plan 
of Operation (MPO), was introduced in 1977 (88) after which there has been a steady decline 
in malaria cases in the country (Figure 2.4) (89). In 1998 the NMEP was re-christened the 
National Anti-Malaria Programme (NAMP) and in 2003 it became the National Vector 
Borne Disease Control Programme (NVBDCP) (90). In 2010, 1.4 million malaria cases were 
reported by routine surveillance of which half were due to P. falciparum (91). 
 
GAMETOCYTES IN INDIA  
History 
 Much of the early literature on gametocytemia, and indeed much of all malaria 
research itself, from India. In part four of a series of paper on malaria treatment, Major JA 
Sinton of the Indian Medical Service and the director of the Malaria Survey of India, draws 
the following conclusions in “The occurrence of sexual forms of Plasmodium falciparum in 
the peripheral circulation” (92):  
1) The occurrence of crescents in the peripheral blood of cases of malignant tertian 
malaria seems to have seasonal periodicity. 
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2) The recorded variations in the incidence of crescent carriers in different localities 
are influenced by various factors. 
3) The development of crescents appears to be associated with a lowered immunity 
of the body. 
4) The duration of the life of a crescent may be as long as 40 to 50 days but the great 
majority disappears within three weeks after the asexual cycle has been destroyed. 
5) The reduction of crescent carriers by efficient treatment and the prevention of 
such carriers conveying the infection to mosquitoes are important factors in all 
anti-malaria campaigns.  
Most of his observations, and the work of that time, remains relevant today and their work 
would help establish the primary role of the 8-aminoquinoline compounds in 
gametocytocidal therapy.  
 
Epidemiology 
A Medline search of “gametocyte India” (Oct, 2011) returned 20 results of which 7 
articles were relevant. Of these four studies (Table 2.1 A) provided limited useful 
information with most suffering from problems of small samples, non-specific goals, being 
outdated, and limited area coverage (93–96). Additionally, diagnosis of gametocytes was not 
validated and studies did not specify the laboratory protocol for microscopy used to assess 
gametocytemia. Most importantly, none of the studies attempted to characterize individuals 
who have gametocytes by examining key covariates including age, gender, asexual parasite 
density, etc. The remaining studies were clinical trials of gametocytocidal agents 
(primaquine, bulaquine and alpha-beta arteether) (97–99) (Table 2.1 B). Thus, current 
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knowledge regarding the distribution and determinants of gametocytes in India is quite 
limited.  
 
 
Treatment 
Before the switch to ACT, the use of primaquine for gametocytocidal effect was part 
of the national drug policy for P. falciparum treatment in India (0.75mg/kg, usual adult dose 
of 45mg) (100). Notably, serious side-effects to single dose primaquine remain unreported 
after decades of use in millions of patients though this matter has not been the focus of 
careful study and pharmacovigilance is poor (74). Recent studies have also challenged this 
picture (71). Given the vulnerable nature of malaria endemic populations, Baird and 
Surjadjaja have argued for a higher bar of demonstrating safety to ethically use primaquine 
noting the current evidence is deficient by any modern medical standard let alone sufficient 
to achieve the approval of drug regulatory agencies today (74).  
With the addition of ACTs to the drug schedule in 2005 (101), as a second-line 
treatment for chloroquine resistant areas, primaquine‟s role was uncertain as artemisinin acts 
against immature gametocytes but does not eliminate transmission (51,58,59,61,62,102–105). 
Given that World Health Organization recommendations were ambivalent (“primaquine may 
be added” in low transmission areas) in 2006 (106), Indian policy did not specify single dose 
primaquine use or disuse (107). In the late 2010 revision of the drug policy (108), when ACT 
was extended as the universal first-line treatment for P. falciparum across India, primaquine 
use was recommended on the second day of ACT treatment given the known, independent 
effects of each  (primaquine‟s effectiveness and artemisinin‟s ineffectiveness on mature 
gametocytes) (109), recent evidence from other countries, and stronger WHO language for 
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low transmission areas (106). Yet, no studies have been conducted in India and evidence of 
its implementation, in both public and private facilities is lacking (110).  
 
SUMMARY 
Knowledge about the epidemiology of gametocytes and efficacy of gametocytocidal 
treatment is important, yet they remain largely unknown in India, which is the highest burden 
country outside sub-Saharan Africa. The transmission setting in India is quite different from 
that of sub-Saharan Africa and local data is needed. Low natural immunity, more adult 
malaria, generally better access to drugs, and mixed malaria species (111) all affect the risk 
of gametocytemia and thus we could expect a different epidemiological scenario than 
described elsewhere. All previous trials of primaquine were conducted in high transmission 
areas with greater immunity and most of these areas were also primaquine “naïve” 
(47,70,71,75,112). In India, where primaquine has been used for decades,  with one study 
suggesting the gametocytocidal effect of a single dose has been reduced (97) so results here 
may not mirror results elsewhere. In addition to the direction of the effect, estimating the 
magnitude of primaquine‟s effect in India is important for local cost-benefit analysis needed 
for policy. Finally, local data of benefit may improve confidence and compliance with 
primaquine treatment or data suggesting little effect due to India‟s differences could indicate 
the need to alter the policy. 
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FIGURE 2.1. The life cycle of malaria parasites (2) 
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FIGURE 2.2. The timing and duration of P. falciparum gametocytemia in relation to the 
host life-cycle: A. Natural history. B. Treated infection.  
 
A. 
 
 
 
B. 
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FIGURE 2.3. Malaria endemicity in India by spleen rate, 1941 (79)  
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FIGURE 2.4. Reported malaria incidence and P. falciparum proportion in India by 
NVBDCP 1961-2009  (91) 
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TABLE 2.1. Summary of table of previous published studies on: A. Gametocyte 
epidemiology in India. B. Trials of primaquine as a gametocytocidal agent in India. 
 
A. 
    Reference District, State Sample size Gametocytes Key Results 
Rajagopalan 
et al., 1990 
(95)  
Koraput, Odisha 714 127 Point 
prevalence 
Mohapatra 
et al., 1992 
(94) 
Koraput, Odisha 22 22 Circulation 
time estimates 
Mohapatra 
et al., 1998 
(96) 
Nalbari, Assam -- -- High 
occurrence in 
children 
Kar et al., 
2009 (93) 
Laskar, Uttaranchal  -- 568 Epidemic and 
resistance 
marker 
     
B.     
Reference District, State Comparator First-line Key Results 
Gogtay et 
al., 1999 
(113) 
Mumbai, Maharashtra None CQ 4/15 CQ 
sensitive 
infections 
remained 
gametocytemic 
on day 28 
Kamtekar et 
al., 2004 
(97) 
Mumbai, Maharashtra No 
primaquine 
Quinine 4% (PQ) 
gametocytemic 
day 28 vs 27% 
Gogtay et 
al., 2006 
(98) 
Mumbai, Maharashtra Bulaquine CQ Clearance of 
gametocytes 
by day 28, 
faster in BQ 
Abbreviations: BQ, bulaquine; CQ, chloroquine; PQ, primaquine
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CHAPTER THREE: DESCRIPTION OF DATA SOURCES 
 
STUDY DESIGN 
The study used existing data from the National Antimalarial Drug Resistance 
Monitoring System which conducted 22 P. falciparum efficacy trials in different sites across 
India in 2009 and 2010 (Appendix A) (114). However, the use of primaquine as an adjunct 
therapy was not specified leading to 9 trial sites using it, while 13 sites did not.  
Aim 1 used a cross section of the trial population, consisting of data available during 
the treatment phase (day zero to day two). Aim 2 was a cohort study of 28 days of follow-up 
among all patients from the efficacy trials who received the full course of treatment. Our 
study design provided a large sample size from multiple settings across India which assisted 
with the generalizablity of the findings. Additionally, since we used data from a trial setting 
using expert staff, the data quality was high.  
An alternative study design for Aim 1 could have been a prospective study of an at-
risk cohort to examine the incidence and changes in gametocytemia over time. An alternative 
study design for Aim 2 could have been a randomized controlled trial to determine the 
efficacy of primaquine. However, both designs would have been limited in scale or too 
expensive and difficult to conduct over multiple geographic areas. By using existing data, 
this study was practical, feasible, and inexpensive to conduct.  
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STUDY SITES  
A total of 11 states were selected: Andhra Pradesh, Assam, Chhattisgarh, Gujarat, 
Jharkhand, Madhya Pradesh, Maharashtra, Meghalaya, Odisha, Rajasthan, and West Bengal 
were selected. Among these states 21 districts were selected: Angul, Baran, Betul, Bilaspur, 
Chhindwara, Dhenkanal, Dumka, Jalpaiguri, Kanker, Kolkata, Latehar, Mumbai, Nagaon, 
Pratapgarh, Ranchi, Sambalpur, Silvasa, Simdega, Surat, Vishakhapatnam, and West Garo 
Hills (Figure 3.1). We could not obtain data from one site (Gadcharoli) because 
gametocytemia was not recorded in case record forms and slides could not be re-examined. 
NVBDCP and NIMR purposively selected the study areas to represent P. falciparum 
transmission settings across the country. Geographic clusters were associated with different 
malaria ecotypes: Western India as Gujarat, Mumbai, and Rajasthan, Central India as Andhra 
Pradesh, Chhattisgarh, Gadcharoli, Jharkhand, Madhya Pradesh, and Orissa, and Eastern 
India as the Assam, Meghalaya, and West Bengal sites (85,115). While the ecotype of 
malaria within clusters may vary, for example urban Western India compared to rural 
Western India, finer resolution was not possible with the available information. The ecotypes 
of the clusters was as follows: Western – unstable rural or urban transmission driven by 
Anopheles culicifacies and A. stephensi, Central – stable forest-related transmission driven by 
A. fluviatilis, and Northeastern – stable de-forestation and forest-related transmission driven 
by A. minimus and A. dirus (116).  
 
STUDY POPULATION 
The source population was the entire population enrolled in the trials during the study 
period (2009-2010). The requirements for inclusion included P. falciparum monoinfection, 
any age, asexual density greater than 500/uL and less than 100,000/uL, without signs of 
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severe malaria, non-pregnant, and willing to consent to follow-up. Some patients ineligible 
on parasite density (either wrong species, out of range, only rapid test used, etc) were 
enrolled, but withdrawn from the study at a later date. Patients were enrolled through routine 
fever screening at clinics or through active case detection in the surrounding community by 
the study team. The main advantages of the study population were its size, representativeness 
of different malaria transmission settings and ecotypes, and quality of monitoring.  
 
DATA COLLECTION 
Data were collected as previously described (114). Each trial had 28 days of follow-
up with patient contact during the first three days of treatment and then at one week intervals. 
Thus the follow-up schedule consisted of the following days: 0, 1, 2, 3, 7, 14, 21, and 28. 
Patients were also advised to return at any time if they had a fever or otherwise felt unwell. 
Demographic information was collected at enrollment and physical examination and thick 
and thin blood smears were performed at each study visit. Patients were treated on days zero 
to two with AS+SP (4mg/kg for three days plus 25/1.25mg/kg) using age-wise dosing as per 
national guidelines with or without primaquine on the third day of treatment (0.75mg/kg, 
usual adult dose of 45mg). Teams received standardized trainings and all studies were 
supervised under one principal investigator using a common protocol (117) and there was 
central quality control of the data management as well as outcome classification. Data were 
collected in a standardized case record form (Appendix B) and then double entered into the 
standard World Health Organization 28 day therapeutic efficacy excel format. 
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DATA MANAGEMENT 
Existing therapeutic efficacy data was consolidated into a single database from its 
previous composition of multiple Microsoft Excel workbooks. We incorporated range checks 
to investigate plausible values for each data field. The cleaned data was imported 
electronically into STATA (v10). 
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FIGURE 3.1. Map of India with P. falciparum trial districts (in red), and P. vivax trial 
districts (in blue) conducted through the National Antimalarial Drug Resistance Monitoring 
System, 2009-2010 
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CHAPTER FOUR: METHODS 
SPECIFIC AIM 1 
Exposure and outcome assessment 
Risk factors for gametocytemia that would be easily identifiable in field settings to 
ensure programmatic relevance were the exposures of interest: age, region, gender, previous 
antimalarial drug intake, current fever, history of fever, and asexual parasite density. 
Exposures were assessed record review of surveyed demographic or clinical information 
except for current fever used a digital thermometer to take the axillary temperature and 
asexual parasitemia which was assessed by microscopy as described below. The outcomes of 
interest were gametocytemia and gametocyte density.  
Diagnosis of gametocytes was by light microscopy. Briefly, routine oil immersion 
reading at 1,000X on Giemsa stained thick smears was used. Slides were counted until 200 
white blood cells (WBC) if gametocytes were detected by then or until 1,000 WBCs to 
declare a slide negative. We assumed 8,000 WBC per µL of blood to obtain a final density 
per microliter of blood. All treatment failures and 10% of slides were randomly cross-
checked during the initial study for quality control purposes. Additionally, we cross-checked 
the entire follow-up series from ten patients with day zero gametocytemia selected at random 
and ten patients without day zero gametocytemia selected at random to specifically determine 
the validity of gametocyte presence. Recorded data was 96% sensitive and 100% specific 
relative to expert re-assessment suggesting the data was appropriate for use. 
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Case and covariate definitions 
We defined gametocytemia as the presence of gametocytes, in any day between 
enrollment and day two of follow-up, in a patient eligible for the therapeutic efficacy study in 
2009 or 2010. The half-life of mature gametocytes is estimated at four to six days once in 
peripheral blood (13). Thus, patients with gametocytemia on the first day of follow-up may 
have been gametocytemic at enrollment. At the least, they would have benefited from a 
gametocytocidal intervention. Gametocytemia detected later in follow-up however, may have 
different origins and may not benefit from a gametocytocidal intervention given during 
treatment. For example, gametocytogenesis from persisting asexual stages, re-infection, or 
the release of sequestered developing gametocytes could explain any later onset 
gametocytemia. 
We categorized age using cutoffs used in age-wise treatment blister packs (<1, 1-4, 5-
9, 10-14, and ≥15 years categories) and asexual parasite density using cut-offs used in 
previous studies (<5,000, 5,000-9,999, 10,000-49,999, and ≥50,000 parasites/μL) (Table 4.1). 
The recall period for history of fever was the past 48 hours and for taking an antimalarial 
drug was the past one week. We defined current fever as an axillary temperature ≥37.5°C at 
the time of enrollment. We designated area using geographic clusters associated with 
different malaria ecotypes: Western India as Gujarat, Mumbai, and Rajasthan, Central India 
as Andhra Pradesh, Chhattisgarh, Gadcharoli, Jharkhand, Madhya Pradesh, and Orissa, and 
Northeast India as the Assam, Meghalaya, and West Bengal sites (77,78). While the ecotype 
of malaria within clusters may vary, for example urban Western India compared to rural 
Western India, finer resolution was not possible without a loss of power. 
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Complete case analysis  
We conducted a complete case analysis using all patients completing two follow-up 
visits after enrollment. None of the predictors had missing data. Missing gametocytemia data, 
due to withdrawal and loss to follow-up during the three-day treatment phase, was less than 
3% of the overall sample. We made the assumption that missing data on gametocytemia was 
missing at random within the levels of covariates. Given these assumptions complete case 
analysis will lead to some loss of power but not appreciable bias. The missing data is less 
than 5% of the overall sample suggesting such censoring is unlikely to be informative. 
 
Data analysis 
To describe distribution of gametocytes in the population, we calculated the 
prevalence of gametocytes among levels of predictors and the overall population. We 
collapsed categories of continuous variables where the prevalence of gametocytemia was 
similar among adjoining groups. In bivariate analyses these characteristics were compared 
among patients with and without gametocytemia using the Chi-squared, Fishers exact, t-test 
or Wilcoxon-rank sum as appropriate for inclusion in the logistic regression model. We also 
calculated the proportion of parasites that were gametocytes by dividing the enrollment 
gametocytemia by the sum of the enrollment gametocyte and asexual parasite densities. We 
multiplied the mean geometric density of the maximum or the mean gametocytemia during 
day zero through two and the number of gametocytemic individuals in each age category to 
estimate the gametocyte population. We calculated the proportion of the potential reservoir 
for transmission in each age category by dividing the dividing the gametocyte population of 
that age category by the total gametocyte population.  
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We used unconditional multivariate logistic regression to build a reference predictive 
model between the demographic and clinical factors and gametocytemia. To account for the 
clustering of data in each trial, we used cluster robust error with district as the unit. We 
estimated the crude prevalence odds ratio and its 95% confidence interval between predictors 
and gametocytemia. We included all predictors associated with gametocytemia (p<0.25) in 
the bivariate analysis. We assessed collinearity between each pair of predictive factors and 
selected among collinear variables based on their operational utility. We evaluated two-way 
interactions of each effect measure and retained all product terms with p values <0.25. To 
simplify field use of the algorithm, we examined reduced models which had adequate fit and 
similar predictive power to the reference model. We used backwards elimination using the 
Wald test to remove predictors with p<0.10 starting with interaction terms and proceeding to 
the variable with the highest p value. We assessed changes in the performance of the reduced 
model due to removing variables or collapsing across categories using the area under the 
receiver operating characteristic (ROC) curve. We evaluated model fit using the Hosmer-
Lemeshow test.  
We then created a scoring system from the logistic model output using the regression 
coefficient, to preserve the multiplicative nature of the score, of each predictor in the reduced 
model. We multiplied the regression coefficient by ten and rounded to the nearest integer to 
simplify score use (118). A final score for each patient was obtained by summing the 
individual scores from their predictor values. To determine the utility of the scoring system, 
we evaluated the sensitivity, specificity, false negatives, false positives and the area under the 
ROC curve of different score cut-points. We calculated false negatives using the formula (1 – 
sensitivity) * gametocytemia prevalence * N and false positives as (1 – specificity) * (1 – 
gametocytemia prevalence) * N. We also calculated the percent of the population correctly 
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classified and the percent of the population which would be treated if scores were used to 
target gametocytocidal therapy. False positive and false negatives were not formally 
weighted but considerations around each will be discussed in light of program goals (control 
or elimination). 
 
Power  
Assuming a control:case ratio of 9:1 we have more than 80% power to detect any risk 
factors with an POR of 2 and a prevalence among control of 7.5% or greater (Figure 4.2 A). 
Multivariate analysis may decrease power but using these conservative assumptions, this 
study has sufficient power to accomplish its aims.  
 
Ethical clearance 
 The Scientific Advisory Committee of the National Institute of Malaria Research, and 
the Institutional Review Board of the University of North Carolina approved the secondary 
analysis.   
 
SPECIFIC AIM 2 
Exposure and outcome assessment 
Primaquine therapy was the main exposure. We obtained primaquine use information 
from the site physician. While site wise practices differed, physicians indicated they 
administered primaquine uniformly, i.e. to all patients or none on the same day and at the 
standard dose, within sites so group exposure was used. The main outcome was 
gametocytemia and secondary outcomes were gametocyte density and reported adverse 
events. Gametocyte assessment was conducted as described in Aim 1. Adverse events were 
28 
 
assessed through history taking at each study follow-up visit through patient complaint or 
recall.  
 
Case and covariate definitions 
We defined pre-treatment gametocytemia as the presence of gametocytes on or before 
day two in a patient a patient eligible for the therapeutic efficacy study in 2009 or 2010.We 
defined post-treatment gametocyte clearance as the first day without gametocytemia after day 
two in a patient with pre-treatment gametocytemia. We defined an event of post-treatment 
gametocytemia as the presence of gametocytes on any follow-up day after day two in a 
patient eligible for the therapeutic efficacy study in 2009 or 2010. We excluded 
gametocytemia at the time of failure for patients with recrudescence or re-infection.  
For measuring exposure time in days we censored at the midpoint of the interval and 
for measuring exposure time in weeks we censored at the end of the interval. We reported the 
week time data to enable comparison with previous literature. For the measurement of post-
treatment gametocyte circulation, patients who completed follow-up accrued an additional 
week of exposure in order to incorporate the contribution of individuals who remained 
positive at the end of day 28. Thus, the total post-treatment exposure time of 32 days is 
congruent with biological estimates of the maximum circulation time of gametocytes (13). 
We used the covariates and coding strategies described in Aim 1.  (Table 4.1) 
 
Causal diagram  
We constructed a causal diagram of the effect of primaquine on gametocytemia using 
substantive knowledge from literature and experience. We used the DAG program 
(http://epi.dife.de/dag/) to conduct path analysis to determine the minimally sufficient and 
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other sufficient adjustment sets (in which case the adjustment is unbiased but precision is lost 
compared to minimally sufficient adjustment if the diagram is correctly specified and the 
other sets are correctly measured).  
 
Complete case analysis  
We conducted a complete case analysis using all patients who completed treatment. 
None of the predictors had missing data. Missing gametocytemia data, due to withdrawal and 
loss to follow-up during the treatment phase, was less than 3% of the overall sample. We 
made the assumption that missing data on gametocytemia was missing at random within the 
levels of covariates.. Given these assumptions complete case analysis will lead to some loss 
of power but not appreciable bias. The missing data is less than 5% of the overall sample 
suggesting such censoring is unlikely to be informative.  
 
Data analysis 
We tabulated the clinical and demographic characteristics, as well as the primary and 
secondary study outcomes, of patients who received and did not receive primaquine. We 
collapsed categories of continuous variables where the prevalence of gametocytemia was 
similar among adjoining groups. We calculated the mean and median gametocyte clearance 
times by treatment group and compared them using the t-test and ranksum tests. We 
calculated the incidence, incidence rate ratios, and incidence rate differences over follow-up 
time among the primaquine and no primaquine groups.  
We modeled the effect of primaquine by estimating the post-treatment clearance rates 
of gametocytes among patients with gametocytes at enrollment and by comparing the 
circulation of post-treatment gametocyte-weeks among the entire population. We estimated 
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crude and adjusted relative measures of effect, hazard ratios and incidence rate ratios 
respectively, as these were readily interpretable and generalizable across our diverse study 
sites. We used Cox regression with the Efron method for ties (119) with clustered (on site) 
robust standard error and Poisson regression using general estimating equations with 
unstructured correlation matrixes and robust clustered (on patient) standard error 
respectively.  
Based on our diagram, adjustment on district was sufficient to control confounding 
bias. However, we controlled for region instead since the exposure, primaquine, did not vary 
by district. To assess the robustness of the measure of effect to uncontrolled confounding, we 
also produced estimates adjusted for age and parasite density, variables strongly associated 
with gametocytemia, as well as adjusted for all covariates whose distribution differed 
between the two arms in bivariate analysis using t-tests, chi-square, or fisher‟s exact test as 
appropriate (p value<0.10).  We included an interaction term between region and primaquine 
and assessed effect measure modification if the Wald test for the interaction term was p<0.2. 
We used a backwards elimination strategy to retain confounders which changed the estimate 
by at least 10%. In the Cox model we compared the model with and without discrete time 
(marginal) due to the large number of tied events and assessed the proportional hazards 
assumption by examining the -log(log(survival)) over time for parallel trends between the 
groups (Table 4.3). We compared the Poisson model to a negative binomial model, using a 
generalized linear model, using a likelihood ratio test with criteria p<0.05 to ensure 
appropriate fit with outcome dispersion.  
The time at risk was measured in intervals and not continuously, i.e. on day 7, day 14, 
etc. A patient gametocytemic at day 7 and not gametocytemic on day 14 may have cleared 
gametocytemia at any point during the interval which potentially misclassifies the exposure 
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time. We used the same time within the interval to censor for both groups which assumed no 
difference in inter-interval clearance and could underestimate the measure of effect. The 
inter-interval time likely differs by primaquine status since the drug accelerates gametocyte 
clearance. Based on previous studies, we conducted a sensitivity analysis assuming 50% 
reduction in time at risk in a given interval among primaquine exposed patients. We plotted 
the mean area under the curve (AUC) for gametocyte density for each group by study visit. 
We excluded outliers of high pre-treatment gametocytemia (maximum density >2,000/µL, 
n=5) which disproportionally influenced the AUC. We calculated the AUC per day using the 
formula of Mendez et al. with the addition of the area for gametocytemia remaining at the 
end of follow-up (120). We compared the median AUC per day for each arm using the 
ranksum test and described differences using percentile cut-offs. 
 
Sensitivity analysis  
The time at risk was measured in intervals, i.e. Day 7, Day 14, and so forth. A person 
who was gametocytemic on Day 7 and not gametocytemic on Day 14 could have changed 
status on Day 8 or Day 13 – a large difference which potentially misclassifies the exposure 
time and is likely to differ by primaquine status. The use of the mid-point of the interval, 
which will be our primary method, could underestimate the measure of effect as it assumes 
no benefit for inter-interval clearance among a primaquine exposed individual which is 
unlikely. Thus, we will conduct a better case sensitivity analysis of the measure of effect 
using an alternate times at risk where all those primaquine exposed experienced clearance 
50% quicker within the interval compared to those who did not receive primaquine. This 
value is similar to previously measured effect estimates of primaquine given with an ACT 
(47,75,76). 
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Power and ethics 
The no primaquine to primaquine ratio is approximately 2:1. The prevalence of 
gametocytemia among the exposed is assumed at 5% (approximately the day 28 prevalence 
in the primaquine arm) and we have more than 90% power to detect an IRR >2 (Figure 4.2 
B). With our sample size of 156 we have more than 90% power to detect a HR of 0.5 
assuming 10% withdrawal and 80% of patients failing during the follow-up period, and 
nearly 80% power to detect a HR of 0.6. (Figure 4.2 C). Multivariate analysis may slightly 
decrease power but using these conservative assumptions, this study has sufficient power to 
accomplish its aims.   
The Ministry of Health and Family Welfare, the Scientific Advisory Committee of 
the National Institute of Malaria Research approved the trials and the Institutional Review 
Board of the University of North Carolina approved the secondary analysis.   
 
LIMITATIONS 
Our methods have several limitations. First, the sensitivity and specificity of 
microscopy, could affect the results. P. falciparum gametocytes are very distinct (crescent 
forms) and specificity of microscopy is thus high. However, because gametocytes are low-
density, microscopy which has a limit of 8 parasites per µL (when 1,000 WBCs are counted) 
may miss positive samples near or below that threshold (45). The sensitivity would also be 
differential in respect to exposures that modify density, such as primaquine use. However, 
because the density of gametocytes is essential to its mechanism, i.e. the probability of 
infection of mosquitoes is positively correlated with gametocyte density, microscopy may 
provide a useful cut-off of functionality. Stated differently, a gametocytemia of 1 per µL is 
not equivalent to a higher gametocytemia as it is functionally less infective (52). Thus, the 
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sensitivity of microscopy could be considered adequate as well as non-differential in respect 
to functional gametocytemia. Similar estimates of the effect of primaquine, in one study 
which used two outcomes – binary microscopic gametocytemia or area under the curve for 
molecular gametocytemia – suggests that bias due to outcome misclassification may be 
minimal (47,70). Other studies which sought to describe the association of gametocytemia 
with age and as a portion of the total parasite population by QT-NASBA and by microscopy 
or estimate the circulation times of gametocytes demonstrated no difference in trends by 
technique (13,121).  
Second, we completed enrollment at each site over one to two months preventing the 
analysis of seasonal trends for gametocytemia.  
Third, our population cross-section is not representative of the population at-risk. It 
represented individuals attending the public sector health clinic for their fever treatment or 
those in communities which were accessible to active case detection. However, it is 
representative of the population encountered by the national control programme through their 
active and passive case detection. This also means that all individuals were symptomatic. We 
did not assess the contribution of asymptomatic carriers to transmission but, at present, there 
may not be valid means to do so (122). The population thus fitted our goal - to observe the 
population amenable to current and future interventions through the control programme.  
Fourth, primaquine use was not randomized. While we controlled for several sets of 
covariates and assessed effect measure modification, confounding due to unmeasured causes 
may bias our estimated effect and the possibility of heterogeneity of the effect cannot be 
excluded with the available power (123).  
Finally, we used the presence of gametocytes as a proxy for infectiousness. Infectivity 
is modified by a number of factors and its direct assessment through membrane-feeding 
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experiments, which are labour and time intensive, would have precluded the type of large 
survey needed for generalizable results (124,125). 
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TABLE 4.1. Potential variables, coding structure, and notes for use in data analysis 
 
Variable Coding Notes 
Gametocytemia 0=No 
1=Yes 
 
 
Day of classification 3.5  
10.5 
17.5 
24.5 
31.5 
 
Continuous variable but 
measured at intervals. 
Censoring at mid-point of 
the week 
Week of 
classification 
4/7 
1 
 
Continuous variable but 
measured at intervals. 
Censoring at end of the 
week 
Gametocyte 
density(/µL) 
 
Continuous  
 
 
Primaquine 0=No 
1=Yes 
 
External variable, site-wise 
exposure 
Sex 0=Female 
1=Male 
 
 
Antimalarial drug 
intake in the past 
week 
0=No 
1=Unknown/Yes 
Less assumptions than 
listing unknown as missing  
Current fever 
(axillary temp 
≥37.5°C ) 
 
0=No 
1=Yes 
 
History of fever in 
24 hrs 
0=Yes 
1=No 
 
 
Asexual parasite 
density (/µL) 
0=<1000 
1=1000-5000 
2=5000-50000 
3=≥50000 
 
 
 
 
 
 
 
Continuous variable, cut-
offs similar to traditional 
semi-quantitative grading 
(+ - ++++), evaluated using 
indicator variables 
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Variable Coding Notes 
Age (years) 0=0-4 
1=5-9 
2=10-14 
3=15-49 
4=≥50 
 
Continuous variable, cut-
offs used age-blister packs 
and correspond to malaria 
immunity  / exposure risks, 
evaluated using indicator 
variables 
 
Classification 0=Withdrawal 
1=Lost to follow-up 
2=ACPR 
3=ETF 
4=LCF 
5=LPF 
 
Categorical based on WHO 
protocol, evaluated using 
indicator variables 
District 22 districts Categorical variable, 
evaluated using indicator 
variables 
 
Region 0=Western 
1=Central 
2=Northeast 
 
Categorical based on 
ecotype, evaluated using 
indicator variables 
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FIGURE 4.1. Causal diagram of the relationship between primaquine use and post-treatment 
gametocytemia  
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FIGURE 4.2. Power available for detecting associations with or effects on gametocytemia. 
A. Odds ratio (lines), different exposure prevalence, and power. B. Incidence rate ratios, 
given assumptions, and power. C. Hazard ratio, given assumptions, and power 
 
 
 
A.        B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 C. 
  * two sided
                                                                            
         .9      459      331       .7       .5      .05       .8       .1  
         .8      343      247       .7       .5      .05       .8       .1  
         .9      224      162       .6       .5      .05       .8       .1  
         .8      168      121       .6       .5      .05       .8       .1  
         .9      122       88       .5       .5      .05       .8       .1  
         .8       91       66       .5       .5      .05       .8       .1  
         .9       70       51       .4       .5      .05       .8       .1  
         .8       52       38       .4       .5      .05       .8       .1  
         .9       41       29       .3       .5      .05       .8       .1  
         .8       31       22       .3       .5      .05       .8       .1  
         .9       23       17       .2       .5      .05       .8       .1  
         .8       17       13       .2       .5      .05       .8       .1  
         .9       12        8       .1       .5      .05       .8       .1  
         .8        9        6       .1       .5      .05       .8       .1  
                                                                            
      Power        N        E       HR       SD    Alpha*   Pr(E)        W  
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FIGURE 4.3. Tests to ensure appropriate fit of the Cox proportion hazards model. A. 
Proportional hazards assumptions. B. Comparison with Kaplan-Meir function. 
 
A. 
 
 
 
B. 
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CHAPTER FIVE: THE EPIDEMIOLOGY OF PLASMODIUM FALCIPARUM 
GAMETOCYTEMIA IN INDIA: PREVALENCE, AGE-STRUCTURE, RISK 
FACTORS AND THE ROLE OF A PREDICTIVE SCORE FOR DETECTION 
 
 
INTRODUCTION 
Gametocytes are the sexual stage of Plasmodia life cycle that render malaria patients 
infectious to mosquitoes and propagate transmission. The proportion of patients infected by 
P. falciparum with gametocytemia and the duration and density of that gametocytemia vary. 
Although gametocytes are central to understanding transmission, few studies have tried to 
demarcate the infectious reservoir (15). This may be because the infectious reservoir is not an 
important determinant of the intensity of transmission relative to high vectorial capacity in 
high transmission areas (17). However, in low and moderate transmission areas, the 
proportion of infectious hosts is critical to the maintenance of endemicity (17). Interventions 
for detecting and treating gametocytemia also differ from those used for asexual parasitemia. 
So an improved understanding of the epidemiology of gametocytemia opens the possibility 
of distinct transmission-blocking control strategies. With recent reductions in malaria 
transmission in many countries and increased focus on elimination worldwide, interest in 
gametocytemia is gaining traction. 
The detection of gametocytes is complicated by their usual low density in peripheral 
blood. Gametocyte density is generally lower than that of asexual parasites (typically less 
than 5% of the total parasite population) and levels below the detection limit of microscopy 
can infect mosquitoes (23). The low density of gametocytes coupled with inadequate 
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laboratory standards and the heavy workloads of technicians makes the diagnosis of 
gametocytemia difficult in routine settings. Recently, molecular methods that detect 
gametocyte-stage specific RNA transcripts have been employed in research (43–45) but these 
may not be feasible for routine public health use. Associations of gametocytemia with easily 
discerned factors including age, season, and symptoms such as fever at the time of 
presentation could provide an alternative strategy for targeting gametocytocidal 
interventions. Clinical algorithms for predicting gametocytemia among diagnosed malaria 
patients could help improve its detection.  
The control of malaria is a key challenge for India which reported 1.5 million cases in 
2010 (126). The reduction of transmission is a priority; most of the country consists of low 
and moderate malaria endemicity. The transmission of malaria in India is arguably the most 
complex in the world given the large geographic area, the presence of both major parasite 
species, a wide range of ecotypes and vectors, and the enormous population (89). In addition, 
lower acquired immunity, more adult malaria, better access to drugs, and mixed species 
infections alter the epidemiology of gametocytemia in India compared to sub-Saharan Africa 
(111). Pre-independence Sinton and others studied the crescents of malignant tertian malaria 
primarily with respect to treatment and spleen size (92). Since 1990, only 4 published studies 
have described gametocytemia in India but these suffer from small sample sizes and limited 
area coverage (93–96). Most importantly, no study characterized the subpopulation with 
gametocytemia.  
 The goal of this study was to describe the epidemiology of P. falciparum 
gametocytemia in India and determine whether a clinical predictive model could improve its 
detection. First, we collected data from a national network of sentinel sites and validated the 
diagnosis of gametocytes. Second, we examined the prevalence of gametocytemia in relation 
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to clinical and demographic factors to understand its distribution among subpopulations of 
our study. Third, we calculated the contribution of different age groups to the reservoir for 
potential transmission using gametocyte density. Last, we created predictive scores for 
gametocytemia and calculated the sensitivity and specificity of different cut-points to 
determine the utility of an algorithmic approach for detection.  
 
METHODS  
Study sites and population 
  We utilized data from 22 P. falciparum therapeutic efficacy trials conducted through 
the National Antimalarial Drug Resistance Monitoring Network of India in 2009 and 2010 
(114). The National Vector Borne Disease Control Programme and the National Institute of 
Malaria Research purposively selected the study sites to represent P. falciparum transmission 
settings across the country. We could not obtain data from 1 site (Gadcharoli) because 
gametocytemia was not recorded in case record forms and slides could not be re-examined. 
We included all patients eligible for the World Health Organization (WHO) therapeutic 
efficacy trial protocol: patients with P. falciparum monoinfection, febrile or with a history of 
fever, asexual parasite density greater than 500/µL and less than 100,000/µL, and willingness 
to consent to follow-up (117). We excluded pregnant patients and those with signs of severe 
malaria. The purpose of these trials was to measure the clinical and parasitological response 
of malaria patients when treated with first-line drugs used in national policy. The study 
population represents a cross-section of the patients who presented to the local clinic or were 
recruited through active case detection in nearby communities. 
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Data collection 
The data collection methods have been previously described (114). Briefly, clinical 
and demographic information were recorded from each patient at enrollment. Patients were 
followed during the first 3 days of treatment (artesunate plus sulfadoxine-pyrimethamine, 
4mg/kg for three days + 25/1.25mg/kg as per national guidelines) and then at weekly 
intervals from enrollment until day 28. At each follow-up visit a physical exam was 
conducted and thick and thin blood smears were prepared. Using routine oil immersion 
reading at 1,000X on Giemsa-stained thick smears, slides were counted until 200 white blood 
cells (WBC) if gametocytes and asexual stages were present or until 1,000 WBC to declare a 
slide negative for both. A count of 8,000 WBC/μL of blood was assumed to obtain a final 
density for asexual and sexual parasites. The data were double-entered into the WHO 
therapeutic efficacy database and blood slides were cross-checked by expert microscopists. 
Existing therapeutic efficacy data was consolidated into a single database after range checks 
to investigate plausible values for each data field.  
Case and predictor definitions 
We defined gametocytemia as the presence of gametocytes in the peripheral blood 
smear, in any visit between day 0 and day 2 of follow-up, in a patient eligible for a 
therapeutic efficacy study in 2009 or 2010. The half-life of mature gametocytes is estimated 
at 4 to 6 days once in peripheral blood (13). Thus, patients with gametocytemia on the first 
day of follow-up may have been gametocytemic at enrollment. At the least, they would have 
benefited from a gametocytocidal intervention. Gametocytemia detected later in follow-up 
however, may have different origins and may not benefit from a gametocytocidal 
intervention given during treatment. For example, gametocytogenesis from persisting asexual 
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stages, re-infection, or the release of sequestered developing gametocytes could explain any 
later onset gametocytemia. 
We selected predictors associated with gametocytemia in prior literature that could be 
feasibly identified during routine curative care: age, sex, region, previous antimalarial drug 
intake, current fever, history of fever, season, and asexual parasite density (15). We 
categorized age with cutoffs used in age-wise treatment blister packs (<1, 1-4, 5-9, 10-14, 
and ≥15 years categories) and asexual parasite density with cut-offs used in previous studies 
(<5,000, 5,000-9,999, 10,000-49,999, and ≥50,000 parasites/μL). The recall period for 
history of fever was the past 48 hours and for taking an antimalarial drug was the past week. 
We defined current fever as an axillary temperature ≥37.5°C at the time of enrollment. We 
designated region using geographic clusters associated with different malaria ecotypes: 
western India as Gujarat, Mumbai, and Rajasthan, central India as Andhra Pradesh, 
Chhattisgarh, Gadcharoli, Jharkhand, Madhya Pradesh, and Orissa, and northeast India as the 
Assam, Meghalaya, and West Bengal sites (85,115). Multiple ecotypes, each with different 
implications for both transmission intensity and malaria control strategy, exist within each of 
these broad regions (127). However, the categorization captures the dominant ecotype, e.g. 
forest malaria in central India, or agglomerates overlapping ecotypes of not so dissimilar 
transmission intensity as with rural, agricultural malaria and urban, migrant malaria in 
western India. Finer resolution was not possible without a loss of power. We classified 
season by month of enrollment: monsoon – June-August, post-monsoon – September-
November, and winter – December and January. 
Data analysis  
We analyzed all patients who completed 2 follow-up visits after enrollment. None of 
the predictors, age, sex, region, previous antimalarial drug intake, current fever, history of 
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fever, season, and asexual parasite density, had missing data. Missing gametocytemia data, 
due to withdrawal and loss to follow-up during the three-day treatment phase, was less than 
3% of the overall sample. We calculated the prevalence of gametocytemia among levels of 
predictors and in the overall population. We collapsed categories of age and parasite density 
where the prevalence of gametocytemia was similar among adjoining groups. We also 
calculated the proportion of parasites that were gametocytes by dividing the enrollment 
gametocytemia by the sum of the enrollment gametocyte and asexual parasite densities. To 
calculate the proportion of the reservoir for potential transmission in each age category we 
first multiplied the mean geometric density of the maximum or the mean gametocytemia 
during day 0 through day 2 in the age category by the number of gametocytemic individuals 
in the age category. Conceptually, the result can be considered the gametocyte load of the 
age category. Second, we summed the gametocyte load of each age category to obtain the 
population gametocyte load. Third, we divided the gametocyte load of each age category by 
the total gametocyte load leading to the proportion of the reservoir for potential transmission 
represented by the age category. The use of transmission is qualified with the term 
“potential” as our approach ignores differences in gametocyte infectivity (due to immunity) 
and vector biting rates (due to uncovered surface area, etc) between the age groups. 
We used unconditional multivariate logistic regression to build a reference predictive 
model between the demographic and clinical factors and gametocytemia. To account for the 
clustering of data in each trial, we estimated cluster robust standard errors with district as the 
unit (128). We estimated the crude prevalence odds ratio and its 95% confidence interval 
between each predictor and gametocytemia. We included all predictors associated with 
gametocytemia (P value < .25 to avoid the exclusion of important variables) in those 
bivariate analyses. We assessed collinearity between each pair of predictive factors by 
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calculating the odds ratio. We selected among collinear variables (odds ratio > 3) based on 
their substantive value. We evaluated two-way interactions between all pairs of predictors 
and retained all product terms with P value < .25.  
To simplify field use of the algorithm, we examined reduced models that had similar 
predictive power and adequate fit compared to the reference model. We used backwards 
elimination using the Wald test to remove predictors with P value < .10 starting with 
interaction terms and proceeding to the variable with the highest P value. We assessed the 
predictive power of reduced models due to removing variables or collapsing across 
categories by comparing the area under the receiver operating characteristic (ROC) curve. 
We evaluated model fit using the Hosmer-Lemeshow test (P value > .1) (129). We then 
created a scoring system from the logistic model output using the regression coefficient, to 
preserve the multiplicative nature of the score, for each predictor in the reduced model. We 
multiplied the regression coefficient by 10 and rounded to the nearest integer to simplify 
score use (118). A final score for each patient was obtained by summing the individual scores 
from their predictor values. To determine the utility of the scoring system, we evaluated the 
sensitivity, specificity, false negatives, false positives and the area under the ROC curve of 
different score cut-points. We calculated false negatives using the formula (1 – sensitivity) * 
gametocytemia prevalence * N and false positives as (1 – specificity) * (1 – gametocytemia 
prevalence) * N. We also calculated the percent of the population correctly classified and the 
percent of the population that would be treated if scores were used to target gametocytocidal 
therapy. We imported the final dataset into STATA (v10) and used it for all analyses. 
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Study power  
Assuming a gametocytemia prevalence of at least 10% and α = .25, we estimated 
more than 95% power in the study to detect risk factors prevalent among at least 7.5% of 
controls with a prevalence odds ratio of 2 or more.  
Ethical clearance 
The Scientific Advisory Committee of the National Institute of Malaria Research 
approved the original trials and the Institutional Review Board of the University of North 
Carolina approved the secondary analysis study. 
 
RESULTS 
During 2009 and 2010, 1,372 patients with P. falciparum malaria were recruited into 
therapeutic efficacy trials of antimalarial drugs. Among these patients, 19 voluntarily 
withdrew, 3 received outside treatment, 2 contracted other illnesses, and 9 were lost to 
follow-up. After removing 4 patients who were missing gametocytemia data our complete 
case population was 1,335. The majority of the study population was, independently, adult, 
male, from central India, and enrolled in the post-monsoon (Table 1). The proportion of 
patients with gametocytemia on day 0, day 1, and day 2 was 13% (n=179), 15% (n=201), and 
15% (n=203) respectively. Overall, the prevalence of gametocytemia, i.e. gametocytes 
detected in blood films on any day from day 0 through day 2, was 19% (n=248) and this 
varied in relation to demographic and clinical classifications (Table 1). In the unadjusted 
bivariate associations, gametocytemia decreased with both increasing age and parasite 
density categories, while it increased among those without fever at enrollment or a history of 
fever prior to enrollment. Men and patients who reported yes or unknown previous 
antimalarial intake also had a higher prevalence of gametocytemia. The proportion of malaria 
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patients with gametocytemia varied by region and decreased along a western to eastern India 
axis.  
The unadjusted prevalence of gametocytemia decreased from 26% (n=103) among 
ages 1-4 years to 14% (n=96) in those 50 years old or greater (Figure 1). Inversely, the 
proportion of the total parasite population consisting of gametocytes increased with age from 
3% in 1-4 year olds to 8% in ages 50 or more years respectively. The average density, 
represented by the geometric mean, of the maximum gametocytemia and mean 
gametocytemia during days 0 through day 2 were 117 and 66 gametocytes/µL respectively. 
The density of gametocytes was higher in children compared to adults (Table 2) which was 
similar to the trend observed with enrollment asexual parasite density (data not shown). In 
unadjusted analysis, gametocyte densities were similar in western and central India but 
higher in northeast India in all age categories (Table 2). Adults (age 15 years or more), who 
were 54% of the study population and among whom 16% carried gametocytes, constituted 
approximately 44% of the reservoir for potential transmission. School-age children (age 5-15 
years), who were 38% of the study population and among whom 20% carried gametocytes, 
constituted approximately 44% of the reservoir for potential transmission. Young children 
(age less than 5 years), who were 8% of the study population and among who 27% carried 
gametocytes, constituted approximately 12% of the reservoir for potential transmission. 
These estimates did not differ by region except for northeast India where the relative 
contributions of school-age children and younger children were reversed compared to other 
regions. These estimates also did not differ whether the maximum or mean gametocyte 
density was used.  
Age, sex, the age-sex product interaction, region, previous antimalarial intake, fever 
at enrollment, and parasite density category remained in the reference model (Table 2). In the 
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simplified model age, sex, region, and previous antimalarial intake alone provided similar 
predictive ability and model fit (P value = .32) (Table S1). Possible risk scores ranged from 0 
to 65 although the minimum and maximum observed score were 0 and 45 respectively. The 
median risk score was 14 (interquartile range: 10, 28). Residing in the western region was the 
highest scoring predictor with 28 points while age 5-14 years and male sex were the lowest 
scoring predictors receiving 4 points each. No cut-point yielded a sensitivity greater than 
75% and a specificity lower than 75%. For example, if the goal of a control programme was 
to treat at least 90% of gametocyte carriers, a risk score of 14 or more provided 91% (95%CI: 
88, 95) sensitivity and 33% (95%CI: 31, 36) specificity (Table 4). Applied in our study 
population of 1,335 patients of whom 248 were gametocytemic, 71% of the population 
would receive treatment with 22 false negatives and 723 false positives. The area under the 
ROC curve for predicting gametocytemia was 0.76 (95%CI: 0.73, 0.80) (Figure 2). For 
comparison, the AUC of the model using all predictors was 0.79 with 2-way interactions and 
0.82 with all possible interactions.  
 
DISCUSSION 
We observed a high prevalence of gametocytemia in India and adults constituted a 
substantial proportion of the reservoir for potential transmission in our sampled population. 
While a predictive model for gametocytemia identified several easily screened risk factors, 
the ability of the clinical algorithm to sensitively and specifically detect gametocytemia was 
low.  
 We observed a higher prevalence of gametocytemia than previously reported 
although there were large, albeit unadjusted, regional differences. Gametocytemia was most 
common in western India which is composed of two distinct ecotypes: rural, low-
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transmission malaria, and urban slum and migrant-labour associated malaria. Both ecotypes 
are conducive to the promotion of gametocytemia either through low immunity or poor 
access or quality of care received by migrants. Central India and northeast India are higher 
transmission areas with forest-associated malaria albeit through different vectors. Access to 
care in the northeast is higher and the use of artemisinin combination therapies began earlier 
which may explain the lower prevalence of gametocytemia in the patient population relative 
to central India (115). In Thailand the malaria control programme records the prevalence of 
gametocytemia, which arises 3-4 days after patency, as an indicator for monitoring access to 
care. Patients treated early in their disease course are less likely to carry gametocytes. Given 
the wide network of clinics with microscopy, India could also make use of gametocytemia in 
a similar fashion.   
The reservoir for potential transmission in our study population was distributed 
throughout the age spectrum. Traditionally, children were thought to be the primary reservoir 
for transmission (25). Young and school-age children did contribute to the reservoir for 
potential transmission disproportionate to their population because of their higher prevalence 
of gametocytemia and higher gametocyte densities. Still, adults constituted nearly half of the 
potential reservoir of infection simply due to their larger population. In adults a higher 
proportion of the parasite population was gametocytes although this was largely due to a 
small denominator as the asexual parasite density decreased with age (data not shown). These 
results underscore the need to examine absolute measures of frequency rather than relative 
measures to inform public health conclusions. The contribution of adults in malaria 
transmission may be higher than the potential reservoir estimated by us when accounting for 
other factors such as their larger surface area for biting (130).  
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Four variables (region, age, sex, and previous antimalarial drug intake) predicted 
gametocytemia in our model. Previous intake of non-gametocytocidal antimalarial drugs is 
thought to induce „stress‟ on the parasite which activates gametocytogenesis (131). Age, sex, 
and region would, presumably, be associated with gametocytemia through one of two 
mechanisms: 1) immunity, primarily determined by transmission intensity and the exposure 
of specific risk-groups and 2) treatment access or treatment seeking behavior as 
gametocytemia increases with longer durations of infection (132). Parasite density and fever 
at the time of enrollment, which were removed from the final model, are also distal effects 
of, rather than proximal markers of, the aforementioned mechanisms which may explain their 
inability to predict gametocytemia in our model.  
The use of a predictive model to detect gametocytemia generated an algorithm which 
ranked a positive case selected at random from our study population higher than a negative 
case selected at random 76% of the time (AUC). No cut-point yielded an acceptable 
sensitivity (>95%) and specificity (>90%) according to criteria developed for malaria rapid 
diagnostic tests (133,134). As an illustration, if we selected 90% sensitivity or more as a 
desirable criterion, we could only achieve 33% specificity. We also did not validate our 
algorithm on independent data and hence, its performance in our study population could be 
considered a best case scenario. Alternative strategies for selecting a predictive model are 
unlikely to produce better clinical algorithms with the available data as the AUC of the final 
model was close to the AUC of the saturated model. Alternative data however, could produce 
better clinical algorithms if other easily measured predictors existed. While our performance 
would not suffice for a disease diagnostic, one could argue the direct costs of using an 
algorithmic approach are non-existent so any reduction of false-positives is a benefit 
compared to universal treatment. However, substantial indirect costs may exist. 
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Considerations of implementing any clinical algorithm must account for the operational 
challenges in individual level targeting including the costs of training, the time required for 
patient assessment, and increased programme complexity. The poor prospects for future 
improvement in model performance coupled with the likelihood of considerable indirect 
costs of implementation suggests a clinical predictive approach for targeting gametocytemia 
is not viable.  
Our study had several limitations. We used microscopy for the measurement of 
gametocytemia which is less sensitive than molecular techniques. However, in studies 
comparing the two methods, the latter increased the magnitude of gametocytemia but did not 
alter its age-structure, circulation time, and other trends (13,28). Interpreting the functional 
relevance of submicroscopic gametocytemia is also difficult. While sub-microscopic density 
infections can infect mosquitoes, the probability of infection, the proportion of mosquitoes 
infected, and the density of infection in mosquitoes is positively correlated with gametocyte 
density (48,52). Next, we completed enrollment at each site over 1 to 2 months which 
restricted the analysis of seasonal trends of gametocytemia. In any given area, most patients 
were enrolled when malaria transmission was the most intense and vector control 
interventions in India are normally timed to dampen any seasonal oscillations. Our 
population cross-section was also not representative of the population at-risk. However, it is 
representative of the population encountered by the control programme through active and 
passive case detection. Thus, we did not assess the contribution of asymptomatic carriers to 
transmission but, at present, there may be no valid means to do so (122). The population was 
appropriate for our goal - to observe the population amenable to current and future 
interventions. Finally, we used the presence of gametocytes in peripheral blood as a proxy for 
infectiousness. Infectivity is modified by a number of factors and its direct assessment 
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through membrane-feeding experiments, that are labour and time intensive, would have 
precluded the type of large survey needed for generalizable results.  
 In a population of P. falciparum patients from a national network of sentinel sites, we 
conclude gametocytemia was common, adults were an important component of the reservoir 
for potential transmission, and clinical algorithms based on predictive modeling were not 
effective for the detection of gametocytemia. Due to the wide age-distribution of 
gametocytemia, and the difficulty of targeting using clinical prediction, we recommend 
universal application, if any, of gametocytocidal interventions among confirmed malaria 
patients. Future research on gametocytemia could try to measure the asymptomatic reservoir, 
conduct longitudinal assessments, and validate gametocytemia as an indicator for treatment 
access.  
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TABLE 5.1. Prevalence and association of gametocytemia in relation to demographic and 
clinical factors of patients from the National Antimalarial Drug Resistance Monitoring 
System, India, 2009-2010 
 
 
Gametocytemia  
 
Total 
Characteristic n Row % 
 
n Col % 
Age (years) 
  
 
  
    <5 28 27  105 8 
    5-14 101 20  503 38 
     ≥15 119 16  727 54 
Sex 
  
 
  
    Male 157 20  773 58 
    Female 91 16  562 42 
PAI 
  
 
  
    No 241 18  1,310 98 
    Yes/unknown 7 28  25 2 
Region 
  
 
  
    Central 84 11  731 55 
    Western 153 41  371 28 
    Northeast 11 5  233 17 
Fever day 0 
  
 
  
    Yes 144 16  929 70 
    No 104 26  406 30 
Season      
    Monsoon 34 8  406 30 
    Post-monsoon 174 28  620 46 
    Winter 40 13  309 23 
PD (#/μL) 
  
 
  
    <5,000 118 25  480 36 
    5,000-49,999 117 16  746 56 
     ≥50,000 13 12  109 8 
History of fever 
  
 
  
    Yes 237 18  1,317 99 
    No 11 61  18 1 
Abbreviations: PAI, previous antimalarial intake; PD, asexual parasite density; POR, 
prevalence odds ratio; CI, confidence interval; Col, column; 
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TABLE 5.2. The contribution of age groups to the reservoir for potential transmission using 
the maximum or mean day zero to three gametocyte density in patients from the National 
Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
    
Maximum 
 
Mean 
Region 
Age 
(years) N %G GD PR   GD PR 
Central <5 64 20 87 0.11 
 
46 0.11 
 
5-14 301 11 141 0.43 
 
77 0.45 
 
≥15 366 10 130 0.46 
 
65 0.44 
         Western <5 13 77 152 0.09
 
24 0.04
 
5-14 136 49 122 0.49 
 
47 0.50 
 
≥15 222 35 88 0.42 
 
37 0.46 
         Northeast <5 28 18 208 0.36
 
153 0.46
 
5-14 66 3 120 0.08 
 
84 0.10 
 
≥15 139 3 402 0.56 
 
182 0.44 
         Total <5 105 27 124 0.12 
 
69 0.12 
 
5-14 503 20 128 0.45 
 
71 0.45 
 ≥15 727 16 102 0.43  58 0.43 
Abbreviations: %G, prevalence of gametocytemia; GD, geometric mean gametocyte density 
per microliter; PR, proportion of the reservoir for potential transmission 
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TABLE 5.3. Adjusted prevalence odds ratios in the reference and final models, regression 
coefficients, and risk scores for predicting gametocytemia in patients from the National 
Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
Variable 
Reference model OR 
(95%CI) AUC=0.766 
Final model OR 
(95%CI) AUC=0.762 
Logistic 
regression 
coefficient 
Risk 
score 
Age (years), Sex 
          <5, male 2.34  1.03, 5.28
3.88
a
 2.13, 7.06 1.36 14 
    <5, female 6.88 3.05, 15.6 
    5-14, male 1.30 0.79, 2.14 
1.51
a
 0.96, 2.36 0.41 4 
    5-14, female 2.07 1.18, 3.64 
     ≥15,male 2.07 1.26, 3.40 
1.00
 a
 
        ≥15, female 1.00 
 Sex 
          Male --
 
1.49 1.06, 2.10 0.40 4
    Female 
  
1.00 
   PAI 
          No 1.00 
         Yes/unknown 1.69 1.00, 2.87 1.67 0.99, 2.81 0.51 5
Region 
          Central 2.98 1.69, 5.28 2.77 1.63, 4.69 1.02 10
    Western 16.3 9.44, 28.1 17.1 9.98, 29.3 2.84 28 
    Northeast 1.00 
     Fever day 0 
          Yes 1.30 0.93, 1.81 -- 
       No 1.00 
     PD (#/μL) 
          <5,000 1.54 0.74, 3.24 -- 
       5,000-49,999 1.44 0.72, 2.88 
         ≥50,000 1.00           
a
for the entire age category  
Abbreviations: PAI, previous antimalarial intake; PD, asexual parasite density; OR, odds 
ratio; CI, confidence interval 
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TABLE 5.4. Performance of different risk score cut-offs for detecting gametocytemia in 
patients from the National Antimalarial Drug Resistance Monitoring System, India, 2009-
2010 
 
Score 
≥ Sensitivity Specificity 
 Number 
of FN 
Number 
of FP 
Percent 
treated 
0 1.00 0.00 0 1087 100 
4 1.00 0.03 1 1059 98 
8 0.98 0.15 5 924 87 
10 0.98 0.18 6 888 85 
13 0.92 0.32 20 738 72 
14 0.91 0.33 22 723 71 
15 0.76 0.59 59 441 47 
17 0.76 0.60 60 435 47 
18 0.75 0.61 63 427 46 
19 0.67 0.75 81 277 33 
23 0.67 0.75 82 270 33 
27 0.63 0.78 91 242 30 
28 0.62 0.80 95 219 28 
32 0.57 0.85 107 165 23 
33 0.19 0.97 200 32 6 
36 0.19 0.97 200 31 6 
37 0.06 1.00 233 5 1 
41 0.05 1.00 235 3 1 
45 0.02 1.00 244 2 0 
46 0.00 1.00 248 0 0 
Abbreviations: FN, false negative; FP, false positive 
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TABLE 5.S1. Cross-tabulation according to predictors identified in the reduced model of 
patients from the National Antimalarial Drug Resistance Monitoring System, India, 2009-
2010 
 
Sex PAI g n g n g n g n g n g n g n g n g n
Male
No 2 17 1 29 1 29 9 36 15 131 14 164 6 7 29 73 12 66
Yes 0 0 0 0 0 0 0 0 0 1 1 7 0 0 1 1 0 1
Female
No 3 11 1 37 3 110 4 27 18 168 22 188 4 6 33 59 64 152
Yes 0 0 0 0 0 0 0 1 0 1 1 7 0 0 3 3 1 3
5-15 >15
Region
Age
Central Western
<5 5-15 >15
Northeast
<5 5-15 >15 <5
 
Abbreviations: G, number gametocytemic; PAI, previous antimalarial drug intake 
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FIGURE 5.1. Prevalence of gametocytemia and the percent of total parasites that were 
gametocytes by age category of patients from the National Antimalarial Drug Resistance 
Monitoring System, India, 2009-2010 
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FIGURE 5.2. Receiver operator characteristics curve with risk score cut-points for 
predicting gametocytemia in patients from the National Antimalarial Drug Resistance 
Monitoring System, India, 2009-2010 
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CHAPTER SIX: A NON-RANDOMIZED CONTROLLED TRIAL OF ARTESUNATE 
PLUS SULFADOXINE-PYRIMETHAMINE WITH OR WITHOUT PRIMAQUINE 
FOR PREVENTING THE POST-TREATMENT TRANSMISSION OF 
PLASMODIUM FALCIPARUM 
 
 
INTRODUCTION 
The primary goal of antimalarial drug therapy is to reduce morbidity and mortality by 
achieving clinical and parasitological cure. A crucial secondary aim however, is to reduce the 
infectious reservoir and decrease malaria transmission. Gametocytes are the sexual stage of 
Plasmodia life cycle that render malaria patients infectious to mosquitoes and propagate 
transmission. Treatment considerations for clearing gametocytes are distinct from those for 
asexual stages because of the stage-specific actions of antimalarial drugs, particularly for P. 
falciparum. Most antimalarial drugs target the asexual blood stages responsible for disease. 
The sensitivity of gametocytes to most antimalarial drugs is less than that of asexual stages. 
Among gametocytes, the sensitivity of mature stages is less than that of immature stages. 
Chloroquine, quinine, and sulfadoxine-pyrimethamine for example, are active against newly 
differentiated gametocytes but lose potency as gametocyte development progresses (53,55).  
The chemotherapeutic control of gametocytes is largely achieved through antimalarial 
treatment with effective blood-stage schizonticides (135). Resolving the asexual parasitemia 
prevents the generation of new gametocytes and limits the period of infectivity to the 
circulation time of existing gametocytes. However, gametocytemia following treatment may 
be prevalent in a high proportion of patients and persist approximately for up to a month. 
Eliminating the post-treatment infectious period could provide substantial impact, 
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particularly in low to moderate endemic countries where the size of the infectious reservoir is 
a critical determinant of transmission. The marginal direct and indirect costs of adjunct 
gametocyte-specific treatment during the case management process make such a strategy 
attractive.    
Artemisinin is active against all gametocyte stages barring those fully mature, and 
this characteristic contributed to the impressive declines in transmission following its 
widespread implementation in several countries (58). Still, in trials with artemisinin 
combination therapy (ACT) mature gametocytes persisted in 10-30% of patients and 
remained infectious to mosquitoes (51,61,62). Primaquine, which has no activity against 
asexual P. falciparum parasites, is effective against mature gametocytes (63,65). A single-
dose of primaquine has been used as an as an adjunct treatment, for its gametocytocidal 
effect, alongside first-line therapies in many countries since the 1960s (66,67). The key 
question for P. falciparum treatment is whether a single dose of primaquine should be added 
to ACTs to further reduce the transmissibility of the treated infection (136). Recently, the 
Malaria Policy Advisory Committee of the World Health Organization (WHO) noted the 
gametocytocidal use of primaquine in the treatment for P. falciparum as a priority question 
for operational research (137).  
The control of malaria is a key challenge for India which reported 1.5 million cases in 
2010 from extensive routine surveillance (126). The reduction of transmission is a priority 
with most of the country in areas of low and moderate malaria endemicity. Before the switch 
to artesunate plus sulfadoxine-pyrimethamine (AS+SP) in 2005, the use of single-dose 
primaquine as a gametocytocide was part of the national drug policy for P. falciparum 
treatment in the country since the malaria eradication era (100). With the addition of an ACT 
to the drug schedule, primaquine‟s role was uncertain as there was little evidence of the 
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efficacy or safety of using both. WHO recommendations were, at the time, ambivalent (106) 
so national policy did not specify single dose primaquine use or disuse (107). In late 2010 
primaquine was added to the first-line treatment based on new recommendations but 
evidence from trials in India is needed to support the policy.  
The goal of this study was to estimate the gametocytocidal effect of adding 
primaquine to ACT in India. We conducted a secondary analysis of data from a national 
network of sentinel sites for monitoring antimalarial drug resistance. The study protocols did 
not contain instructions on primaquine use as there were no policy guidelines at the time of 
the study. The use of the drug by some sites and not in others created a natural experiment. 
First, we compared the clinical and demographic characteristics of patients among the groups 
to determine if the populations were similar. Second, we computed crude and adjusted 
measures of effect for post-treatment clearance (gametocyte survival) and post-treatment 
carriage (gametocyte circulation) to estimate the additional effect of primaquine. Third, we 
conducted a sensitivity analysis of the measurement of patient follow-up time to assess 
whether our estimates were robust to its misclassification. Finally, we compared reported 
adverse events among the groups to assess safety and tolerability.  
 
METHODS  
Study sites and population 
  We utilized data from 22 P. falciparum therapeutic efficacy trials conducted through 
the National Antimalarial Drug Resistance Monitoring Network of India in 2009 and 2010 
(114). Among the sites, 9 used primaquine along with AS+SP while 13 used AS+SP alone. 
We could not obtain data from 1 site (Gadcharoli, no primaquine use) because 
gametocytemia was not recorded in case record forms and slides could not be re-examined. 
63 
 
The National Vector Borne Disease Control Programme and the National Institute of Malaria 
Research purposively selected the study sites to represent P. falciparum transmission settings 
across the country. We included all patients eligible for the WHO therapeutic efficacy trial 
protocol: patients with P. falciparum monoinfection, febrile or with a history of fever, 
asexual parasite density greater than 500/µL and less than 100,000/µL, and willingness to 
consent to follow-up. We excluded pregnant patients and those with signs of severe malaria, 
and patients less than one year of age as primaquine is contraindicated in this group. The 
purpose of these trials was to measure the clinical and parasitological response of malaria 
patients when treated with first-line drugs used in national policy. The study population 
represents a cross-section of the patients who presented to the local clinic or were recruited 
through active case detection in nearby communities. 
Data collection 
The data collection methods have been previously described (114). Briefly, clinical 
and demographic information were recorded from each patient at enrollment. Patients were 
followed during the first 3 days of treatment and then at weekly intervals from enrollment 
until day 28. Patients received AS+SP (4mg/kg for three days plus 25/1.25mg/kg) as per 
national guidelines with or without primaquine on the third day of treatment (0.75mg/kg, 
usual adult dose of 45mg). At each follow-up visit a physical exam was conducted and thick 
and thin blood smears were prepared. Using routine oil immersion reading at 1,000X on 
Giemsa-stained thick smears, slides were counted until 200 white blood cells (WBC) if 
gametocytes and asexual stages were present or until 1,000 WBC to declare a slide negative 
for both. A count of 8,000 WBC per μL of blood was assumed to obtain a final parasite 
density. The data were double-entered into the WHO therapeutic efficacy database and blood 
slides were cross-checked by expert microscopists. Existing therapeutic efficacy data was 
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consolidated into a single database after range checks to investigate plausible values for each 
data field.  
Case and predictor definitions 
Primaquine therapy was the main exposure. We obtained primaquine use information 
from the site physician. While site specific practices differed, physicians indicated they 
administered primaquine uniformly, i.e. to all patients or none, within sites so group 
exposure was used. We defined pre-treatment gametocytemia as the presence of gametocytes 
in peripheral blood on any day between day 0 and day 2 in a patient eligible for a therapeutic 
efficacy study in 2009 or 2010. We defined post-treatment gametocyte clearance as the first 
day without gametocytemia after day 2 in a patient with pre-treatment gametocytemia. We 
defined an event of post-treatment gametocytemia as the presence of gametocytes on any 
follow-up day after day 2 in a patient eligible for the therapeutic efficacy study in 2009 or 
2010. We excluded gametocytemia at the time of failure for patients with recrudescence or 
re-infection. For measuring exposure time in weeks we censored at the end of the interval. 
We reported the data in person-weeks, instead of person-days, to enable comparison with 
previous literature. For the measurement of post-treatment gametocyte circulation, patients 
who completed follow-up accrued an additional week of exposure in order to incorporate the 
contribution of individuals who remained positive at the end of day 28. Thus, the total post-
treatment exposure time of 32 days is congruent with biological estimates of the maximum 
circulation time of gametocytes (13).  
We compared covariates associated with gametocytemia in prior literature: age, sex, 
season, region, previous antimalarial drug intake, current fever, history of fever, and asexual 
parasite density (15). We categorized age using cutoffs corresponding to age-wise treatment 
blister packs (<1, 1-4, 5-9, 10-14, and ≥15 years categories) and asexual parasite density 
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using cut-offs used in previous studies (<5,000, 5,000-9,999, 10,000-49,999, and ≥50,000 
parasites/μL). The recall period for history of fever was the past 48 hours and for taking an 
antimalarial drug was the past week. We defined current fever as an axillary temperature 
≥37.5°C at the time of enrollment. We designated region using geographic clusters associated 
with different malaria ecotypes: western India as Gujarat, Mumbai, and Rajasthan, central 
India as Andhra Pradesh, Chhattisgarh, Gadcharoli, Jharkhand, Madhya Pradesh, and Orissa, 
and northeast India as the Assam, Meghalaya, and West Bengal sites (85,115). Multiple 
ecotypes, each with different implications for both transmission intensity and malaria control 
strategy, exist within each of these broad regions (127). However, the categorization captures 
the dominant ecotype, e.g. forest malaria in central India, or agglomerates overlapping 
ecotypes of not so dissimilar transmission intensity as with rural, agricultural malaria and 
urban, migrant malaria in western India. Finer resolution was not possible without a loss of 
power. We classified season by month of enrollment: monsoon – June-August, post-monsoon 
– September-November, and winter – December and January. 
Data analysis  
We analyzed all patients who completed treatment. None of the covariates, age, sex, 
season, region, previous antimalarial drug intake, current fever, history of fever, and asexual 
parasite density, had missing data. Missing gametocytemia data, due to withdrawal and loss 
to follow-up during the treatment phase, was less than 3% of the overall sample. We 
tabulated the clinical and demographic characteristics, as well as the primary and secondary 
study outcomes, of patients who received and did not receive primaquine. We collapsed 
categories of continuous variables where the prevalence of gametocytemia was similar 
among adjoining groups. We calculated the mean and median gametocyte clearance times by 
treatment group and compared them using the t-test and ranksum tests. We calculated the 
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incidence, incidence rate ratios, and incidence rate differences over follow-up time among 
the primaquine and no primaquine groups.  
We modeled the effect of primaquine by estimating the post-treatment clearance rates 
of gametocytes among patients with gametocytemia at enrollment and by comparing the 
circulation of post-treatment gametocyte-weeks among the entire population. We estimated 
crude and adjusted relative measures of effect, hazard ratios and incidence rate ratios 
respectively, as these were readily interpretable and generalizable across our diverse study 
sites. We used cox regression with the Efron method for ties (119) with clustered (on site) 
robust standard error and Poisson regression using general estimating equations with 
unstructured correlation matrixes and robust clustered (on patient) standard error 
respectively. We constructed a causal diagram of the effect of primaquine on gametocytemia 
to identify minimally sufficient and sufficient adjustment sets using the DAG program v2.1 
(http://epi.dife.de/dag). Based on our diagram, adjustment on district was sufficient to control 
confounding bias. However, we controlled for region instead since the exposure, primaquine, 
did not vary by district. To assess the robustness of the measure of effect to uncontrolled 
confounding, we also produced estimates adjusted for age and parasite density, variables 
strongly associated with gametocytemia, as well as adjusted for all covariates whose 
distribution differed between the two arms (P value < .10).  We included an interaction term 
between region and primaquine and assessed effect measure modification if the Wald test for 
the interaction term was P value < .2. We used a backwards elimination strategy to retain 
confounders that changed the estimate by at least 10%. In the cox model we compared the 
model with and without discrete time (marginal) due to the large number of tied events and 
assessed the proportional hazards assumption by examining the -log(log(survival)) over time 
for parallel trends between the groups. We compared the Poisson model to a negative 
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binomial model using a likelihood ratio test with criteria P value < .05 to ensure appropriate 
fit with outcome dispersion.  
The time at risk was measured in intervals and not continuously, i.e. on day 7, day 14, 
etc. A patient gametocytemic at day 7 and not gametocytemic on day 14 may have cleared 
gametocytes at any point during the interval which potentially misclassifies the exposure 
time. We used the same time within the interval to censor for both groups which assumed no 
difference in inter-interval clearance and could underestimate the measure of effect. The 
inter-interval time likely differs by primaquine status since the drug accelerates gametocyte 
clearance. Based on previous studies, we conducted a sensitivity analysis assuming 50% 
reduction in time at risk in a given interval among primaquine exposed patients. We plotted 
the mean area under the curve (AUC) for gametocyte density for each group by study visit. 
We excluded outliers of high pre-treatment gametocyte density (maximum > 2,000/µL, n=5) 
that disproportionally influenced the AUC. We calculated the AUC per day using the formula 
of Mendez et al. with the addition of the area for gametocytemia remaining at the end of 
follow-up (120). We compared the median AUC per day for each group using the ranksum 
test. We imported the final dataset into STATA (v10) and used it for all analyses. 
Study power  
For gametocyte clearance, our sample size of approximately 230 patients with pre-
treatment gametocytemia and α = .05 provides more than 90% power to detect a hazard ratio 
of 0.5 assuming 10% withdrawal and 80% of patients experiencing the outcome during the 
follow-up period. With a no primaquine to primaquine ratio of approximately 2:1, α = .05, 
and assuming the prevalence of gametocytemia among the exposed as 5%, we calculated 
more than 90% power to detect a gametocyte-week incidence rate ratio greater than 2.  
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Ethical clearance 
The Scientific Advisory Committee of the National Institute of Malaria Research 
approved the original trials and the Institutional Review Board of the University of North 
Carolina approved the secondary analysis. 
 
RESULTS 
During 2009-2010, 1,372 eligible patients were recruited among 21 sites (Figure 1). 
Nine sites where 543 patients completed treatment used primaquine while eleven sites where 
796 patients completed treatment did not use primaquine. In each group 2 patients missing 
gametocytemia data were excluded; the final complete case population was 1,335 patients 
(541 primaquine, 794 no primaquine). Among treatment failures, 4 of 12 recrudescent 
patients, 0 of 2 P. falciparum re-infection patients, and 0 of 6 P. vivax re-infection patients 
were gametocytemic at the time of failure. The clinical, demographic, and treatment efficacy 
as well as parasite clearance outcomes were similar between study groups with the 
exceptions of a higher proportion of males, adults, and patients from northeast India in the 
primaquine unexposed group (Table 1). Critically, the pre-treatment gametocytemia 
prevalence in the no primaquine group (18%, n=141) was similar to the primaquine group 
(20%, n=107). The prevalence of gametocytemia between the arms was similar on days 0, 
day 1, and day 2 and subsequently declined among the primaquine exposed arm starting on 
day 3 (Figure 2).  
Among 248 patients with pre-treatment gametocytemia, the median time to 
gametocyte clearance was 7 days (interquartile range: 3, 14) in patients who received 
primaquine and 14 days (interquartile range: 3, 28) in patients who did not (P value < .001). 
Primaquine with AS+SP cleared gametocytes faster than AS+SP alone with only 3% survival 
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of gametocytemia compared to 23% at the end of follow-up (Figure 3). Using cox regression 
the crude hazard ratio for the effect of primaquine on the rate of gametocyte clearance was 
2.2 (95%CI: 1.2, 4.2) over 28 days. Adjusted for region, the addition of primaquine resulted 
in an increased rate of gametocyte clearance 1.9 times (95%CI: 1.1, 3.3) that of AS+SP alone 
over 28 days. The effect measure for primaquine was robust to adjusting for age and parasite 
density or all covariates selected by univariate associations (Table S1). We did not detect any 
modification of the effect with time or region.  
The development of post-treatment gametocytemia among patients who were pre-
treatment negative for gametocytemia was lower (0.7%, 3/434) in the primaquine group 
compared to the no primaquine group (2.8%, 18/653) (P value = .02). Primaquine reduced 
the absolute and relative rates of post-treatment gametocyte circulation among the population 
(Table 2). Using Poisson regression with general estimating equations, the incidence rate 
ratio for the effect of primaquine on the number of post-treatment gametocyte-weeks was 0.3 
(95%CI: 0.2, 0.6). Adjusted for region, primaquine decreased the number of post-treatment 
gametocyte weeks by 45% (95%CI: 19, 62). The effect measure for primaquine was robust to 
adjusting for age and parasite density or all covariates selected by univariate associations 
(Table S1). We did not detect any modification of the effect with region or over-dispersion of 
the outcome.    
In our sensitivity analysis assuming faster intra-interval clearance/exposure time, the 
estimated effect of primaquine increased compared to the previous measures produced with 
more conservative assumptions (Table S2). The crude and region adjusted hazard ratio for 
primaquine on the rate of gametocyte clearance was 2.8 (95%CI: 1.5, 5.5) and 2.5 (95%CI: 
1.4, 4.3) over 28 days. The crude and region adjusted incidence rate ratio for primaquine on 
the number of gametocyte-weeks was 0.2 (95%CI: 0.1, 0.3) and 0.3 (95%CI: 0.2, 0.4) over 
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28 days. The mean AUC of each group at a study visit decreased over time compared to no 
primaquine (Figure 4). The median AUC per day for both groups was 0 gametocytes/µL due 
to the high proportion of patients without post-treatment gametocytemia. The 90
th
-99
th
 
percentile AUC per day was 2.2-79 gametocytes/µL for primaquine and 9.1-198 
gametocytes/µL for AS+SP alone (P value = .01).  
Adverse events reported during follow-up included vomiting (8) and fever (2) in the 
AS+SP alone arm and vomiting (14) and jaundice (1) in the primaquine arm. Only 5 of the 
14 patients who experienced vomiting did so on the day of primaquine administration. The 
case of jaundice occurred in a 5-year-old, male child on day 14. 
 
DISCUSSION 
The addition of primaquine to AS+SP reduced the potential of post-treatment 
transmission of P. falciparum in India. The gametocytocidal dose of primaquine increased 
gametocyte clearance by one week in patients who were positive pre-treatment, decreased the 
incidence of gametocytemia in patients who were negative pre-treatment, and was well 
tolerated.  
We observed a high potential for P. falciparum transmission after treatment with an 
ACT alone. The prevalence of gametocytemia at the end of follow-up for those receiving 
only AS+SP was 5% among all patients and 24% among those initially positive for 
gametocytes. While the choice of partner drug may also affect post-treatment gametocytemia 
prevalence, as SP monotherapy is particularly gametocytogenic (38), our observations were 
similar to those observed for other combination therapies elsewhere (138). We measured the 
effect of primaquine through gametocyte clearance, the number of gametocyte-weeks of 
circulation, and the area under the curve using gametocyte density over time. By any 
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approach, the addition of primaquine provided substantial benefit even in the presence of an 
artemisinin based treatment. Our sensitivity analysis suggests our estimates were 
conservative and the effect of primaquine may be larger. Other estimates of the effect of 
primaquine with an ACT include the 92% reduction in gametocyte-weeks in Burma (75), 
83% reduction in the prevalence on any day of follow-up in Tanzania (47), and the 
acceleration of gametocyte clearance by a week in Colombia (76). While our estimate of 
clearance time was similar to the estimate from the low transmission setting of the 
Colombian trial, the reduction of post-treatment gametocytemia was lower than the other two 
studies in high transmission areas. The difference in primaquine effectiveness could be due to 
the different host immunity or pharmacokinetics of the study population, but there is also the 
possibility of reduced primaquine efficacy in India. Since the extensive malaria eradication 
program in the 1960s, India has a long history of primaquine use. Several studies previously 
reported the frequent persistence of gametocytemia following primaquine administration 
(97,113) and slower clearance of gametocytes after treatment with primaquine compared to a 
novel 8-aminoquionline in Western India (98).  
While primaquine certainly works, several operational questions remain regarding its 
safety, optimal dose, and the day of administration. The primary concern with primaquine 
use is safety given the risk of haemolysis in individuals with G6PD deficiency (63). Notably, 
most severe events have been associated with the longer primaquine dosing used for anti-
relapse treatment in P. vivax and not the gametocytocidal single-dose. In previous single-
dose primaquine trials, haemoglobin concentrations among exposed patients were 5% lower 
at day 7 (recovered by the end of the month) or the mean increase over the study was 0.3g/dL 
less compared to patients who only received ACT (47,75). Recent research also suggests 
haemolysis may occur in non-G6PD individuals as well though severe anemia was rare (71). 
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The only other adverse effect attributable to primaquine in any study was increased 
abdominal pain (75,76). However, haemolysis and side-effects will vary by population and in 
the context of already vulnerable populations (74) more assessments, particularly post-
marketing pharmacovigilance, are needed. The current dose of primaquine was determined 
through limited experiments in the 1960s (66,67). Lower, or higher, doses of primaquine may 
be equally, or more, effective as well as safe – Thailand, for example, uses a 30mg adult dose 
of primaquine for gametocytocidal therapy (60). A 4-arm, randomized study of different 
doses is underway in Uganda and should help determine the trade-offs, if any, between 
primaquine efficacy and safety (139). The day of primaquine administration varies from day 
0 to day 2 with little evidence available to guide policy. For day 0, treatment with primaquine 
can be observed but in non-fixed-dose therapies, such as AS+SP, patients already suffer a 
large pill burden. For day 3, the prospect of eliminating mature gametocytes is the highest 
since the window of exposure is short and treatment would be occurring, most likely, after 
the completion of asexual parasite clearance. Modeling studies have suggested later 
administration a week after ACT treatment may have the most transmission reducing effect 
(140). However, such a regimen could be operationally difficult to implement. 
Our study had several limitations. We used microscopy for the measurement of 
gametocytemia which is less sensitive than molecular techniques. However, in studies 
comparing the two methods, the latter increased the magnitude of gametocytemia but did not 
alter its age-structure, circulation time estimates, or other trends (13,28). Interpreting the 
functional relevance of submicroscopic gametocytemia is also difficult. While sub-
microscopic density infections can infect mosquitoes, the probability of infection, the 
proportion of mosquitoes infected, and the density of infection in mosquitoes is positively 
correlated with gametocyte density (48,52). Second, primaquine use was not randomized. 
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While we controlled for several sets of covariates and assessed effect measure modification, 
confounding due to unmeasured causes may bias our estimates and the possibility of 
heterogeneity of the effect cannot be excluded with the available power (123). Third, initial 
gametocytemia among patients may have varied depending on the form of their recruitment. 
The direction of bias is unclear as active case detection could detect patients earlier in their 
disease course prior to self-referral or later in the disease course post symptom attenuation, 
compared to passive case detection. Finally, we used the presence of gametocytes as a proxy 
for infectiousness. Infectivity is modified by a number of factors and its direct assessment 
through membrane-feeding experiments, that are labour and time intensive, would preclude 
large, multi-site trials needed for generalizable results. 
We conclude primaquine reduced the potential for post-treatment transmission of P. 
falciparum compared to AS+SP alone. Single-dose primaquine could be provided along with 
ACT in India to improve malaria control. We outline several avenues of future operational 
research to needed for optimizing the adjunctive use of primaquine.  
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TABLE 6.1. Demographics, clinical characteristics, and primary outcomes by primaquine 
receipt status of patients from the National Antimalarial Drug Resistance Monitoring System, 
India, 2009-2010 
 
  
No 
primaquine 
 
Primaquine 
Characteristic  Value n=794 %  n=541 % 
Region Central 312 39 
 
419 77 
 
Western 249 31 
 
122 23 
 
Northeastern 233 29 
 
0 0 
Sex Male  506 64 
 
267 49 
 
Female 288 36 
 
274 51 
Age category (years) 0-4 44 6 
 
61 11 
 
5-9 112 14 
 
153 28 
 
10-14 131 16 
 
107 20 
 
15-49 445 56 
 
186 34 
 
≥50 62 8 
 
34 6 
Asexual parasite density / μL <5,000 290 37 
 
190 35 
 
5,000-10,000 144 18 
 
86 16 
 
10,000-50,000 308 39 
 
208 38 
 
≥50,000 52 7 
 
57 11 
Febrile (≥37.5°C) No 249 31 
 
157 29 
 
Yes 545 69 
 
384 71 
History of fever No 18 2 
 
0 0 
 
Yes 776 98 
 
541 100 
Previous drug intake No 781 98 
 
529 98 
 
Yes 8 1 
 
9 2 
 
Unknown 5 1 
 
3 1 
Primary classification ACPR 765 96 
 
527 97 
 
ETF 2 0 
 
1 0 
 
LCF 5 1 
 
1 0 
 
LPF 9 1 
 
3 1 
 
LFU 13 2 
 
7 1 
 
WTH 0 0 
 
2 0 
Parasite clearance ≤24 hrs 468 59 
 
338 62 
 
 24 - 48 hrs 215 27 
 
137 25 
 
48 - 72 hrs 93 12 
 
61 11 
 
≥72 hrs 16 2 
 
5 1 
Pre-treatment gametocytemia No 653 82 
 
434 80 
  Yes 141 18  107 20 
 
Abbreviations: PQ, primaquine; IR, incidence rate; IRR, incidence rate ratio; IRD, incidence 
rate difference 
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TABLE 6.2. Post-treatment gametocyte circulation by primaquine group among patients from the National Antimalarial Drug 
Resistance Monitoring System, India, 2009-2010 
 
 
 
No PQ 
 
PQ 
    Unit N IR   N IR IRR 95%CI IRD 95%CI
Gametocyte-weeks 285 7.97 
 
92 3.78 0.47 0.37, 0.60 -0.042 -0.030, -0.054 
Person-weeks 3,574 
  
2,436 
      
Abbreviations: PQ, primaquine; IR, incidence rate per 100-person-weeks; IRR, incidence rate ratio; IRD, incidence rate 
difference; CI, confidence interval  
 
7
5
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TABLE 6.S1. Crude and adjusted measures of effect for primaquine on post-treatment 
gametocyte clearance rates and post-treatment gametocyte circulation using different 
modeling and coding options among patients from the National Antimalarial Drug Resistance 
Monitoring System, India, 2009-2010 
 
  
Efron ties 
 
Discrete ties (m) 
Model Covariates HR 95%CI  HR 95%CI 
Cox 
 
2.20  1.15, 4.23 
 
2.27  1.72, 3.01 
Cox Region 1.89 1.07, 3.32 
 
1.93 1.44, 2.60 
Cox Age, PD 2.05 1.27, 3.33 
 
2.13 1.56, 2.90 
Cox All  1.69  1.02, 2.81 
 
1.74 1.27, 2.38 
  
Person-days (nb) 
 
Person-weeks (p) 
Model Covariates IRR 95%CI  IRR 95%CI 
GEE 
 
0.38 0.25, 0.59 
 
0.34 0.20, 0.58 
GEE Region 0.56 0.37, 0.83 
 
0.55 0.38, 0.81 
GEE Age, PD 0.44 0.29, 0.66 
 
0.32 0.17, 0.60 
GEE All  0.72 0.47, 1.12  0.69 0.46, 1.01 
 
Abbreviations: Region, reduced region with Northeast/Central collapsed; Age, age in years; 
PD, log parasite density; All, age-PD-sex-history of fever- Region; NB, negative binomial; P, 
Poisson; M, marginal; CI, confidence interval 
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TABLE 6.S2. Sensitivity analysis of crude and adjusted measure of effect for primaquine on 
post-treatment gametocyte clearance rates and post-treatment gametocyte circulation 
assuming 50% faster interval-clearance for primaquine recipients among patients from the 
National Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
 
Clearance 
 
Circulation 
Covariates HR 95%CI  IRR 95%CI 
 
2.82  1.46, 5.46 
 
0.15 0.08, 0.29 
Region 2.47 1.41, 4.32 
 
0.27 0.18, 0.39 
Age, PD 2.69  1.64, 4.40 
 
0.17 0.09, 0.31 
All  2.22  1.37, 3.75 
 
0.35 0.23, 0.52 
 
Abbreviations: Region, reduced region with Northeast/Central collapsed; Age, age in years; 
PD, log parasite density; All, age-PD-sex-history of fever- Region; CI, confidence interval 
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FIGURE 6.1. Flow-chart of patients eligible for treatment with primaquine from the 
National Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
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FIGURE 6.2. Prevalence of gametocytemia by treatment arm at each study visit among 
patients from the National Antimalarial Drug Resistance Monitoring System, India, 2009-
2010 
 
 
 
Abbreviations: PQ, primaquine; Arrow, administration of primaquine 
80 
 
FIGURE 6.3. Clearance of gametocytes by treatment arm among patients with pre-treatment 
gametocytemia from the National Antimalarial Drug Resistance Monitoring System, India, 
2009-2010 
 
 
 
Abbreviations: PQ, primaquine 
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FIGURE 6.4. Area under the curve for the mean gametocyte density by treatment arm at 
each study visit among patients from the National Antimalarial Drug Resistance Monitoring 
System, India, 2009-2010 
 
 
Abbreviations: PQ, primaquine; Arrow, administration of primaquine 
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CHAPTER SEVEN: DISCUSSION 
 
Gametocytes are the sexual stage of Plasmodia life cycle which render malaria cases 
infectious to mosquitoes and propagate transmission. The proportion of P. falciparum 
malaria cases with gametocytemia and the duration and density of that gametocytemia are 
varied. In areas of low transmission, such as most of India, the number of infective hosts, as 
opposed to vectorial capacity, determines transmission. Thus, studies of the epidemiology of 
gametocytemia are needed to better define this key reservoir. Interventions for detecting and 
treating gametocytemia also differ from those used against asexual parasitemia. So an 
improved understanding of gametocytes opens the possibility of distinct transmission-
blocking control strategies for the nation.  
First, which case-patients carry gametocytes? Universal application of 
gametocytocidal interventions adds cost and may expose some individuals to potentially 
severe side effects. Targeting interventions by direct examination of gametocytes during 
routine microscopy can be difficult due to low density, poor training, and the heavy workload 
of the microscopist. Easily discerned risk factors associated with gametocytemia could help 
but these have not been assessed in Indian transmission settings where, in comparison to sub-
Saharan Africa, natural immunity is low, many patients are adults, and the presence of 
competing malaria species may be an important determinant. Risk factors used in a clinical 
risk score could enable field-level screening.  
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Second, how should we treat gametocytemia? Artemisinin combination therapies 
(ACT), the first-line treatment in most countries including India, eliminate immature 
gametocytes but not mature gametocytes which may persist for up to one month post-
treatment. The key operational question is whether a single dose of primaquine, which is 
inexpensive and effective against mature gametocytes, should be added to artemisinin 
combination therapies to reduce the potential post-treatment transmission of the infection. 
However, we need data regarding the safety or effectiveness of doing so. This dissertation 
aimed to describe the epidemiology of gametocytemia in India, including its prevalence, age-
structure, and risk factors, as well as estimate the effect of primaquine in addition to an ACT 
for improving the control of malaria in the country by reducing potential transmission.  
 
SUMMARY OF FINDINGS 
In this dissertation we reported several findings which may help improve malaria 
control operations in India, and potentially elsewhere. In our first specific aim, we measured 
the prevalence of gametocytemia in India in patients recruited from the National Antimalarial 
Drug Monitoring System during 2009 to 2010. Gametocytemia which varied by region and 
age was highest in Western India, where transmission is low, and lower in the Central and 
Northeastern regions, where transmission is more intense. Gametocytemia was highest in 
children and decreased with age; however, when examining potential reservoir for 
transmission in the study population, adults constituted nearly half of the total indicating a 
substantial role in the spread of malaria. We found four easily screened risk factors 
associated with gametocytemia – age, region, gender, and previous antimalarial drug intake. 
While the predictive ability of the clinical algorithm to detect gametocytemia was low, using 
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this model we could eliminate gametocytocidal treatment in in 31% of patients while 
maintaining more than 90% sensitivity for detecting carriers in our study population.  
In our second specific aim, we estimated the effect of adding primaquine to AS+SP 
for reducing the potential of post-treatment transmission of P. falciparum in India through a 
natural experiment of trials from the National Antimalarial Drug Monitoring System during 
2009 to 2010. We found the gametocytocidal dose of primaquine increased the rate of 
gametocyte clearance in patients who were positive pre-treatment, decreased the circulation 
of gametocyte-weeks in all patients regardless of pre-treatment status, and shrunk the AUC 
of gametocyte density over time. The estimated effect of primaquine was robust to 
adjustment by area, as well as other sets of covariates. The estimated effect of primaquine, on 
gametocyte clearance or circulation, increased in sensitivity analysis of the exposure time 
assigned. No serious adverse events were reported among either group though the proportion 
of patients with vomiting was slightly higher among primaquine recipients.  
 
PUBLIC HEALTH SIGNIFICANCE AND FUTURE DIRECTIONS 
Specific Aim 1 
Our findings in Aim 1 suggest that individual level targeting of gametocytocidal 
interventions may not be effective since the predictive power of our clinical algorithm was 
low even with the use of multiple risk factors. While the direct costs of using an algorithmic 
approach are non-existent, and any reduction of false-positives while minimizing false 
negatives would be beneficial compared to universal treatment, substantial indirect costs 
exist. Considerations of implementing any algorithm must account for the operational 
challenges in individual level targeting including the costs of training, the time required for 
patient assessment, and increased programme complexity. Population-based targeting may 
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also not be effective. Each age group contributed substantially to the potential reservoir for 
transmission suggesting that age-based targeting such as intervening on young or school-age 
children for example, may not provide sufficient reduction if adults were ignored. Similarly, 
the prevalence of gametocytemia was greater than 5% in all regions. However, in Western 
India, we observed 40% of patients with gametocytemia. Given the lower vectorial capacity 
in this region, gametocytocidal interventions may have greater proportional impact on 
transmission here. Overall, our results suggest the need for the universal application, if any, 
of gametocytocidal interventions among confirmed malaria patients. Future research on 
gametocytemia could try to measure the asymptomatic reservoir and conduct longitudinal 
assessment. Finally, in Thailand the malaria control programme records the prevalence of 
gametocytemia, which arises three to four days after patency, as an indicator for monitoring 
access to care. Patients treated early in their disease course are less likely to carry 
gametocytes. Given the wide network of microscopy clinics, India could also make use of 
gametocytemia as a monitoring indicator for treatment delay.  
 
Specific Aim 2 
Our findings in Aim 2 demonstrated the gametocytocidal effectiveness of primaquine 
when added to AS+SP compared to AS+SP alone. The administration of single-dose 
primaquine along with artemisinin combination therapy in India should be considered to 
improve malaria control. Several avenues of future operational research are needed for 
optimizing the adjunctive use of primaquine. While primaquine certainly works, several 
operational questions remain regarding the optimal dose, time of administration, adherence, 
and safety. The current dose of primaquine was determined through limited experiments in 
the 1960s (66,67). Lower, or higher, doses of primaquine may be equally, or more, effective 
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– Thailand, for example, uses a 30mg adult dose of primaquine for gametocytocidal therapy 
(60). The day of administration of primaquine varies from day zero to day two with little 
evidence available to guide policy. For day zero, non-fixed-dose therapies, such as AS+SP, 
have a larger pill burden on day zero but on the other hand treatment can be observed. For 
day three, with treatment occurring, most likely, after the completion of asexual parasite 
clearance, more mature gametocytes can be exposed to the drug since the window of 
exposure is short. Modeling studies have suggested later administration one week after 
treatment may have the most transmission reducing effect (140). However, such a regimen 
could be operationally difficult.  
Primaquine also poses a safety risk given the risk of hemolysis in individuals with 
G6PD deficiency (63). The prevalence of G6PD deficiency in India is not well mapped but 
may be present in up to 10% of some tribal groups (141), populations in which the malaria 
burden is also concentrated (142). However, most severe events have been associated with 
the longer primaquine dosing used for anti-relapse treatment in P. vivax and not the 
gametocytocidal single-dose. Recent research suggests hemolysis may occur in non-G6PD 
individuals as well though severe anemia was rare (71). In the previous primaquine trials, 
hemoglobin concentrations among exposed patients were 5% lower at day seven (recovered 
by one month) or the mean increase over the study was 0.3g/dL less compared to patients 
who only received artemisinin combination therapy (47,75). The only adverse effect 
attributable to primaquine in any study was increased abdominal pain (75,76). However, 
hemolysis and side-effects will vary by population and in the context of already vulnerable 
populations (74) more assessments, particularly post-marketing pharmacovigilance, are 
needed.  
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CONCLUSIONS 
The need to reduce the reservoir of transmission for malaria control was recognized 
more than 100 years ago (143). In modern malaria control programs the opportunity to do so 
may be greater than ever before. Case management is now a central, and perhaps the primary, 
component of many control efforts while in the eradication era it was an after-thought to 
massive operations to reduce vector longevity. There are several reasons for the change in 
outlook. We now have many new and more effective treatments, more equipment (rapid 
diagnostic tests) and more infrastructure (better health systems) for diagnosis, but we also 
have fundamentally different goals. Reducing the morbidity and mortality burden of the 
disease, through access to care, is considered feasible, sustainable, and desirable by planners 
and communities (144). Thus, the opportunity to simultaneously reduce transmission, while 
enhancing case management, is attractive given its alignment with overall strategy and the 
very low direct and indirect costs of doing so (for single dose primaquine). This dissertation 
adds evidence about whom to target for transmission reduction interventions and how 
effective primaquine may be in the current context of ACT treatment. Finally, it would be 
remiss to fail to note that the appropriate use of new indicators, interventions, and operational 
strategies ultimately rely on stronger health systems to enable their effective deployment and 
maintain the resultant gains made in public health  (145,146). 
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APPENDIX A: CASE RECORD FORM 
 
Case Record Form used in Therapeutic Efficacy Trials through the National Antimalarial 
Drug Resistance Monitoring System, India, 2009-2010 
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Nationwide Sentinel Site System For Monitoring Antimalarial Drug Resistance In 
India: Outcomes And Risks For Treatment Failure, 2009-2010 
 
by 
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Submitted to Bulletin of the WHO, June 2012 
 
Abstract 
Background 
Study protocols for monitoring the efficacy of antimalarial drugs are well standardized; 
however, routine systems for selecting sites and conducting trials are not. The recently 
created National Antimalarial Drug Resistance Monitoring System of India is characterized 
by alternating sentinel sites for therapeutic efficacy trials, centralized data management, 
quality control checks, genotyping of molecular markers, and the integration of 
supplementary studies. We aimed to describe the performance of the new system, measure 
the efficacy of the first-line malaria treatments, and determine risk factors associated with 
treatment failure.  
Methods 
During 2009 and 2010, we recruited patients in prospective single arm, open label trials with 
28 days of follow-up. In 22 studies, patients received artesunate plus sulfadoxine-
pyrimethamine (AS+SP) for the treatment of Plasmodium falciparum and in 3 studies, 
patients received chloroquine for the treatment of P. vivax according to national policy. We 
genotyped four dhfr and three dhps codons of 20% of the P. falciparum isolates including all 
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treatment failures. We used multivariate exponential risk regression to determine the 
association of clinical and demographic factors with treatment failure.  
Results 
We enrolled 1,664 patients in 25 therapeutic efficacy studies across India. The overall crude 
and PCR-corrected Kaplan-Meier efficacies for AS+SP were 98.6% (95%CI: 97.8, 99.1) and 
98.8% (95%CI: 98.1, 99.3) respectively. The majority of P. falciparum patients cleared 
parasitaemia within 24 hours. Four of six patients who did not clear parasitemia within 72 
hours failed treatment. Genotyping revealed a high prevalence of double mutants in dhfr 
(68.4%, n=234) and a few triple and quadruple mutants (3.2%, n=11) while mutations in 
dhps were rare (2.3%, n=6). An administered dose of artesunate <3mg/kg, age less than five 
years, fever at the time of enrollment, and a parasite density less than 5,000/µL increased the 
risk of treatment failure. Chloroquine remained 100% efficacious in the treatment of P. vivax 
and the majority of patients cleared parasitemia prior to 48 hours. Few adverse events to 
either therapy were reported, the most common being vomiting (n=47).  
Conclusions 
First-line drugs for the treatment of malaria in India remain safe and efficacious. The 
new monitoring system which coordinated resources provided wide coverage which detected 
two sites for additional monitoring. Pooled analysis led to the identification of risk factors 
which indicate the need for future studies particularly in the pediatric population and trials 
comparing age-based and weight-based dosing.  
 
Introduction 
The global control of malaria remains a major challenge and is aggravated by parasite 
resistance to antimalarial drugs. Plasmodium falciparum rapidly develops resistance to new 
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therapies and the presence of multi-drug resistant, now including artemisinin, strains in 
Southeast Asia is alarming (147). Plasmodium vivax develops chloroquine (CQ) resistance 
over time, is innately less susceptible to anti-folate compounds, and the sensitivity of its 
dormant stages to primaquine, the only anti-relapse therapy, is difficult to assess (148). The 
long-term public health response to antimalarial drug resistance requires reducing drug 
pressure through rational treatment and creating a pipeline of alternative drugs. Its routine 
management however, centers on monitoring the efficacy of current therapies and selecting 
appropriate treatments based on that evidence. Several monitoring techniques are used to 
inform policy-making: in vitro drug sensitivity tests, pharmacokinetic studies, molecular 
markers of drug resistance, and in vivo therapeutic efficacy trials (149).  
The Republic of India has conducted extensive monitoring of antimalarial drug 
resistance over many decades. Chloroquine resistant P. falciparum was first reported in 
Karbi-Anglong district, near the Indo-Myanmar border, in 1973 and subsequent studies 
confirmed its presence throughout the Northeast (150). CQ resistant P. vivax was unknown in 
India until 1995 when Garg et al. reported two cases from Mumbai who remained smear 
positive despite adequate blood concentration of drug (151). Similar case reports from 
Northern and Eastern India have seen emerged (152,153). In 1978, the National Malaria 
Eradication Programme (now the National Vector Borne Disease Control Programme or 
NVBDCP) created six regional monitoring teams to routinely conduct studies. In addition, 
the Malaria Research Centre (now the National Institute of Malaria Research or NIMR) and 
other organizations supported a wide range of monitoring efforts. Between 1978 and 2007, in 
vivo trials of the first-line and second-line P. falciparum treatments, CQ and sulfadoxine-
pyrimethamine (SP), alone consisted of 380 studies with 18,944 patients (107). The median 
proportion of treatment failures with SP had increased from 7.7% during 1984-96 to 25.9% 
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during 1997-2007 in 28 days of follow-up (107). Indian isolates also demonstrated 
widespread mutations in the drug targets dihydrofolate reductase (dhfr) and dihydropteroate 
synthase (dhps), including quintuple mutants in some areas (154). As the efficacy and life-
span of artemisinin combination therapies depend largely on the partner drug, pre-existing 
resistance to SP creates the possibility of rapid development of resistance to the new 
combination. Attributing study results to individual components of the combination therapy 
is difficult, and assessing the efficacy of the partner drug alone is no longer ethical. In 2005, 
artesunate plus sulfadoxine-pyrimethamine (AS+SP) replaced SP in the national drug policy 
and is now the universal first-line treatment for P. falciparum in India. While the efficacy of 
AS+SP was high (0% median failure, 4% max) in nine 28 day follow-up studies from 2005-
2007, the monitored population was limited given the size of the country (149).  
 Addressing these challenges necessitated the creation of a joint NVBDCP-NIMR 
surveillance system with several innovations: 1) alternating sentinel sites to provide both 
longitudinal trends along with widespread coverage, 2) routine P. vivax trials to track the 
emergence of CQ resistance, 3) central quality control of slide results and data analysis, 4) 
genotyping to differentiate recrudescent samples from re-infections, 5) simultaneous 
measurement of molecular markers of drug resistance, and 6) integration of supplementary 
studies such as pharmacokinetics and residual drug levels. We collected and analyzed data 
from the first two years of operating the new system to describe treatment outcomes across 
India and determine the factors associated with treatment failure. First, we estimated the 
efficacy of AS+SP and CQ for P. falciparum and P. vivax respectively. Second, we measured 
molecular markers of SP resistance to independently assess the partner drug. Finally, we 
determined the clinical, demographic, and parasite-related predictors of treatment outcomes. 
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Methods  
Study sites and population 
The NVBDCP reported 1.6 million malaria cases in 2009 and 2010 through its 
extensive surveillance system which conducts more than 100 million screenings for malaria 
each year (126). NIMR and NDVBDCP selected 24 districts (third level administrative unit, 
approximate population 1 to 4 million) and one city across 13 states and one union territory 
of India respectively (Figure 1) during annual reviews of the antimalarial drug resistance 
data. Sites were purposively selected to provide a representative sample of varying 
transmission intensity, malaria ecotype, and geographic region (Figure 1). We classified sites 
into area categories reflecting malaria ecotypes: western – unstable rural or urban 
transmission driven by Anopheles culicifacies and A. stephensi, central – stable forest-related 
transmission driven by A. fluviatilis, and northeastern – stable de-forestation and forest-
related transmission driven by A. minimus and A. dirus (82). Trials were open label, single 
arm prospective studies using the 2009 World Health Organization (WHO) protocol for 
therapeutic efficacy trials with a target sample size of more than 50 patients (117). We 
included consenting patients with P. falciparum (asexual parasites 500-100,000/μl) or P. 
vivax (asexual parasites >250/μl) monoinfection and current fever (axillary temperature ≥ 
37.5
0
C) or a history of fever in the preceding 24 hours. We excluded pregnant or lactating 
women, children weighing less than five kilograms, and patients with signs of severe malaria.  
 
Data collection, treatment, and follow-up 
At enrollment, we recorded a complete medical history of presenting symptoms, 
current medications, and previous antimalarial drug use for each patient. We tested female 
patients for pregnancy and collected thick and thin blood smears and dried blood spots on 
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filter paper. We treated patients with age-specific treatment according to the national drug 
policy (14). Patients with P. falciparum received AS+SP (artesunate 4mg/kg for 3 days plus 
SP 25/1.25mg/kg single dose) and those with P. vivax received CQ (25mg/kg over 3 days) as 
well as primaquine (0.25mg/kg for 14 days) after completing follow-up. We observed 
treatment and used quality-assured drugs through the state government supply which 
consisted of the following manufacturers (number of sites in brackets): AS+SP - IPCA (11), 
Medicamen (5), Zydus (2), Hindustan Antibiotics, Unicure, Corona Remedies, Leonate, and 
CQ – IDPL (2), Troikaa. All drugs were used within their expiry period and batch numbers 
are available upon request. Patients who vomited the dose within 30 minutes were re-treated 
and those with repeated emesis were withdrawn from the study and treated as severe malaria. 
We followed patients on days 1, 2, 3, 7, 14, 21, and 28 in the clinic or traced them to their 
residence or place of work. We also advised patients to return at any time if they experienced 
fever or other symptoms. Patients who did not complete treatment were withdrawn from the 
study. At each follow-up visit, we performed a physical examination and collected blood 
smears and dried blood spots. At the end of follow-up patients received Rs 500 for lost 
wages.   
 
Laboratory procedures 
We collected thick and thin blood films on the same slide and stained them with 
Giemsa. Parasites were counted on thick films against 200 white blood cells (WBC) using 
100X light microscopy by technicians with more than ten years of experience. We calculated 
assuming 8,000 WBC/μl of blood. Slides were declared negative if no parasites were 
detected in 100 high-power fields. Expert microscopists cross-checked all failure samples as 
well as a 10% random sample of positive and negative slides from each site at the central 
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quality control unit at the NIMR headquarters in New Delhi. We analyzed paired blood 
samples from day zero and the day of recrudescence, if any, by Polymerase Chain Reaction 
(PCR) to rule out re-infections. Parasite genomic DNA was isolated from filter paper blood 
spots using the QIAamp DNA blood mini kit and 2µl of eluted DNA were used for the 
primary PCR assay and 1-2µl of primary PCR product was used for nested PCR. The 
markers msp-1, msp-2, and glurp were analyzed in paired samples to distinguish 
recrudescence from new infections using previously published methods (155). In addition, 
we genotyped the molecular markers for SP resistance in all day zero samples from patients 
who failed treatment along with 25% of other samples selected at random. We conducted P. 
falciparum dhfr and dhps amplification using primers described earlier (156). A mutation-
specific nested PCR was performed with the primary product to detect dhfr codons 51, 59, 
108, 164 and dhps codons 436, 437, 540. 
 
Trial endpoints 
Primary study endpoints were classified according to standard criteria defined in the 
current WHO guidelines (13). Briefly, for endpoints included adequate clinical and 
parasitological response (ACPR), early treatment failure (ETF), late clinical failure (LCF), 
late parasitological failure (LPF), loss to follow-up (LFU), and voluntary/involuntary 
withdrawal or exclusion due to protocol violation (WTH). Treatment failures (ETF, LCF, and 
LPF) were then classified as recrudescence or re-infection according to PCR results. We 
examined parasite clearance interval (<24hr, 24-48hrs, 48-72hrs, >72hrs), taken the first 
follow-up day with two consecutive days of negative blood smear prior to day three or the 
first negative blood smear on day three or day seven, as a secondary endpoint. For therapies 
with high efficacy, as was expected for AS+SP, parasite clearance interval can provide 
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evidence of emerging resistance as its prolongation in the population can precede the 
frequent appearance of treatment failure. We used binary cut-offs of >72hrs clearance as the 
endpoint for risk factor analysis.  
 
Data analysis 
We selected patient and demographic factors which could affect treatment failure and 
defined categories of age and parasite density with cut-offs used in the literature. Season was 
classified by month of enrollment: monsoon – June-August, post-monsoon – September-
November, and winter – December and January. We defined anti-folate molecular markers as 
the sum of total dhfr plus dhps mutations detected. If dhps codon data were not available 
because of a failure to amplify, dhfr data alone were used. The use of age-based dosing, 
rather than weight-based dosing, means the administered drug dose may not have matched 
the target dose. We calculated the administered dose for P. falciparum patients by dividing 
the age-wise dose by the patient‟s weight and categorized it as follows: ≥87.5% of target 
dose, 75-87.5% of target dose, and <75% of target dose. For artesunate and SP the respective 
cut-offs were ≥3.5mg/kg, 3-3.5 mg/kg, <3 mg/kg and ≥22 mg/kg, 19-22 mg/kg, and <19 
mg/kg.  
We described the basic characteristics of patients as well as the primary and 
secondary outcomes by the species of infection. To estimate drug efficacy, we conducted per 
protocol analysis and modified per protocol using Kaplan-Meier survival analysis, with and 
without PCR-correction, of treatment failure and parasite clearance. We used log-risk models 
to calculate the univariate and multivariate associations between risk factors and endpoints. 
For multivariable analysis we constructed full models with age, area, gender, fever at 
enrollment, parasite density at enrollment, anti-folate mutations, administered artesunate 
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dose, and interaction between age and administered artesunate, age and parasite density, and 
anti-folate mutations and parasite density. We used a backwards elimination strategy with a 
cut-off of p<0.10 for predictors and p<0.15 for interaction terms. Multi-level categorical 
variables were reduced to dichotomous variables to preserve power prior to their removal 
from models. To account for the clustering of data by study site, we used clustered robust 
standard error in both multivariate models to adjust the precision of estimated risks. STATA 
(version 10) was used for all analyses.  
 
Human subjects protection 
We obtained informed, written consent from patients or their guardian. The trials 
were approved by the Ministry of Health and Family Welfare, Government of India as well 
as the ethics committee of National Institute of Malaria Research.  
 
Results 
Patient enrollment and characteristics 
A total of 1,733 patients were enrolled during the first and second years from 25 sites 
(Figure 2). 895 patients were enrolled between June 2009 to January 2010 at 13 sites and 838 
patients were enrolled between June to December 2010 at 12 sites. Out of 1,664 eligible 
patients, 1,394 P. falciparum and 185 P. vivax patients completed follow-up until day 28 
(94.8%). Most trial patients were male, adults, febrile at the time of enrollment, from Central 
India, and recruited in the monsoon (P. vivax) or post-monsoon (P. falciparum) season 
(Table 1). A history of fever was near universal while the intake of antimalarial drugs in the 
previous week was rare. The geometric mean parasitemia was 7,975 parasites/μl (range: 560, 
99,707) for P. falciparum and 7,133 parasites/μl (range 378, 123,317) for P. vivax. 
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P. falciparum 
Primary and secondary outcomes 
1,394 patients completed the study follow-up (Table 2). The majority of patients 
demonstrated clinical and parasitological cure and few withdrew or were lost to follow-up. 
Out of 27 cases of treatment failure, there were 17 true failures (63%) across 10 trial sites. 
The other treatment failures were P. vivax infections or P. falciparum re-infections (both on 
day 28) while one case was untypeable (day 28 failure). Two early treatment failures 
occurred in Betul with parasitemia and fever on day three and one in Angul with day three 
parasitemia more than 25% of day zero parasitemia. In Gadcharoli, five patients failed 
treatment on day 7. The crude and PCR-corrected per protocol Kaplan-Meier survival 
estimates were 98.6% (95%CI: 97.8, 99.1) and 98.8% (95%CI: 98.1, 99.3) respectively 
(Figure 3A). Among sites, the survival estimates ranged from 93.8% to 100% (Table S1). P. 
falciparum patients treated with AS+SP cleared parasitemia rapidly with 62% aparasitemic 
within 24 hours of administering the drug (Table 3B). Of the six patients who did not clear 
parasitemia within 72 hours, four (67%) recrudesced (including three early treatment 
failures) while the rest achieved cure. Vivax and falciparum re-infections occurred among 
patients who cleared parasitemia prior to day three. For the categories <24hours, 24-48hours, 
and 48-72 hours the proportion who recrudesced were 0.7% (6/873), 1.3% (5/384), and 1.3% 
(2/154) respectively. Four patients (81%) of the six with clearance greater than 72 hours were 
from Betul. AS+SP treatment was well tolerated. Adverse events reported during follow-up 
included vomiting (46), fever (3), and jaundice (1). 
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Molecular markers of drug resistance 
 342 of 373 isolates genotyped for dhfr successfully amplified. Single (n=65) and 
double mutations (n=234) were common. The most frequent haplotypes included the double 
mutant 108/59, then single mutant 108 (Table S3). Only 10 and 1 isolates were triple or 
quadruple mutants respectively (3.2%). Typing of dhps proved difficult and only 261 of 373 
isolates were successfully amplified. Among these isolates, mutations in dhps were rare 
(2.3%) with five single mutations and one double mutation. Mutations in codon 437 were the 
most frequent. Among the 17 PCR-corrected treatment failures, one sample did not amplify, 
12 were dhfr double mutants, 4 were single mutants, and all were wild-type for dhps.  
 
Predictors of treatment failure and parasite clearance interval 
For PCR-corrected treatment failure, younger age category (<5 years) relative to 
adults 15 years or older, and low administered dose of artesunate (<3mg/kg, 3-3.5mg/kg) 
relative to 3.5mg/kg or more were associated with higher risk (Table S2). In multivariate 
analysis, age less than five years, fever at the time of presentation, and an administered 
artesunate doses less than 3.5mg/kg and less than 3mg/kg were associated with treatment 
failure (Table 3). For administered artesunate dose the relative risk of failure increased with 
as the dose category decreased. A parasite density of 5,000/µL or more was associated with a 
lower risk of treatment failure. We did not detect any association between increased 
mutations (beyond 1-2) in dhfr and dhps and treatment failure of AS+SP. For parasite 
clearance interval of 72 hours or more, there were insufficient observations to determine its 
predictors.  
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P. vivax 
Three trials of CQ in 185 patients demonstrated 100% efficacy of the drug. However, 
compared to P. falciparum patients, a higher proportion of P. vivax patients, many of whom 
were residents of urban slums, withdrew or were lost to follow-up (Table 1). Most patients 
(56.2%) cleared parasitemia by 48 hours (Figure 3B). In six patients parasitemia persisted 
after 72 hours but without any symptoms and cleared by day seven of follow-up. CQ 
treatment was well tolerated. We observed one event of each of the following: gastritis, 
stomatitis, and vomiting. 
 
Discussion 
The National Antimalarial Drug Resistance Monitoring System recruited 1,733 
patients and completed therapeutic efficacy trials in 25 sites across India during its first two 
years. The results suggest first-line therapies for P. falciparum and P. vivax recommended by 
the national antimalarial drug policy, AS+SP and CQ, remain efficacious.  
 
P. falciparum 
The 28 day efficacy of AS+SP for the treatment of P. falciparum was more than 98%. 
While treatment failures and isolates with prolonged clearance were few, those identified 
were clustered among a few sites. Surprisingly, these did not include Northeastern India 
where the highest rates of SP monotherapy failure have been reported (157). The association 
of parasite clearance interval greater than 72 hours with treatment failure (4/6) suggests the 
measurement of clearance may be an important indicator in the age of combination therapy. 
The apparent clustering validates the design of the new monitoring system – to provide wide 
coverage to detect such variation and longitudinal studies to follow-up on emerging trends. 
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Besides recrudescent infections, P. falciparum re-infection was rare. While the re-infection 
rate may be a function of the length of the follow-up period, it also depends on the intensity 
of transmission which is generally lower in India compared to many other regions.  
Consistent with previous studies, most isolates (87.1%) were partially pyrimethamine 
resistant with single (S108N) and double mutations (S108N/C59R). We detected a low 
prevalence of triple and quadruple mutants though (3.2%). dhfr single and double mutations 
increase the IC50 of pyrimethamine ten-fold while the triple mutation increases the IC50 by 
1,000 times. Seven isolates possessed the I164L mutation associated with high-level 
resistance (158). Many samples failed dhps amplification (27.6%) though the failure rate was 
similar to that previously published using the same protocol which generates large amplicons 
(154). Still, single or double mutation among the successfully genotyped isolates was low 
(2.3%) assuming that mutations were not the cause of non-amplification. Monitoring step-
wise increases in both markers will alert us to increasing resistance independent of clinical 
response.  
Treatment failure reflects a combination of drug resistance, host immunity, and 
pharmacokinetics. Predictors of treatment failure included elements of the latter two in this 
study. Younger age, fever at the time of presentation, and a lower parasite density, all 
potential markers of lower immunity, were also associated with one or both outcomes. 
Finally, a lower administered dose of artesunate was associated with treatment failure in a 
dose-response manner. Overall, 8.8% of the patient population were administered an 
artesunate dose between 3-3.5mg/kg and 1.9% received less than 3mg/kg. In comparison, 
1.3% of received an SP dose between 19-22mg/kg and 0.3% received less than 19mg/kg. The 
blister pack dose of AS+SP (200mg) assumes a 50kg adult body weight to achieve the target 
artesunate dose. However, the SP dose (1500mg) assumes 60kg adult body weight to achieve 
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the target and is therefore less frequently underdosed. The relationship between administered 
dose and blood levels of drug however, is complex. 
 
P. vivax 
In spite of sporadic case reports of CQ-resistant vivax in India, we did not detect any 
treatment failures during systematic trials. We did not obtain blood levels of CQ because 
there were no treatment failures. While trials were, thus far, located in southern India, the 
areas were major urban centers and many patients were migrant workers from all over the 
country. More vivax malaria studies in other locations are needed though adding sites will 
result in a longer period between repeating therapeutic efficacy trials at each. Given the 
relative slower pace of drug resistance development compared to P. falciparum this may be 
acceptable. A critical component of vivax malaria therapy is primaquine treatment. However, 
no standard protocols for evaluating the therapeutic efficacy, alone or in combination with 
CQ, exist. Another remaining challenge is the treatment of mixed infections. Due to their 
exclusion, we do not know the efficacy of AS+SP for treating vivax malaria which is the 
current protocol for such cases. Recent reports across Southeast Asia have described a high 
incidence of vivax malaria following the treatment of P. falciparum, presumably from liver-
stage relapses (159). We observed seven episodes of P. vivax during the follow-up of our P. 
falciparum patients. Six of the post-treatment P. vivax cases were from two sites, Angul and 
Dhenkenal in Orissa, representing a relapse rate of 5.2% at each site. 
 
Sentinel site monitoring 
We designed and implemented a new national monitoring system for India. The 
benefits included high data quality, national representation of different malaria ecotypes, 
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coordinated use of resources, and pooled data analysis. While the number of sites exceed the 
minimum recommended by WHO, even more may be required in a country as large as India. 
The ability to alternate sentinel sites as planned will provide longitudinal trends as well. We 
did face several challenges. While overall coordination in the joint NVBDCP-NIMR system 
was satisfactory, we encountered occasional administrative delays which led to delayed 
recruitment at some sites. Other difficulties encountered were the central procurement of 
some reagents, e.g. pregnancy testing supplies, sample transport for quality control to New 
Delhi, and local data entry in a digital format. These issues were to be expected as with any 
new program and the coordination was reviewed and addressed. Using data and biological 
samples collected through the system, NIMR investigators have initiated several 
supplementary work including 1) the prevalence of residual antimalarial drug levels at 
enrollment and its association with molecular markers and outcomes, 2) pharmacokinetics of 
SP in treatment failure samples, and 3) pharmacovigilance of antimalarials used in the 
country. 
 
Limitations 
Our study had several limitations. The 28 day follow-up, although recommended by 
WHO, could be longer. If the drug efficacy is high then any treatment failures are likely to 
occur late, especially in partner drugs with longer half-lives such as SP. Thus, we 
implemented a 42 day follow-up for three studies in 2011 and for all upcoming studies in 
2012 to detect later failures. Few treatment failures limited the power to detect its predictors. 
Next, monitoring of parasitemia every 24hrs is not frequent enough for accurate estimation of 
mean clearance times or stage-specific clearance (160). However, examining the proportion 
of aparastiemic patients by day intervals can still provide useful trends albeit with less power 
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than a continuous measure. The cost and staff workload of nested-PCR assays to genotype 
molecular markers limited the number of samples assessed. Finally, while we describe the 
outputs of the new system, we have not calculated the costs of the new system which is 
complex as it uses resources across different institutions and between state and central levels. 
 
Conclusions 
AS+SP is a safe and effective for the treatment of uncomplicated falciparum malaria 
in India. CQ remains a safe and effective for the treatment of uncomplicated vivax malaria. 
Based on the two year implementation of the new system and the findings from initial 
studies, we recommend the following: 1) maintain sentinel site based antimalarial drug 
monitoring, 2) validate parasite clearance greater than 72 hours and subsequent treatment 
failure particularly in Betul, 3) switch to high-throughput technology, such as real-time PCR, 
for molecular work to enable the genotyping of more isolates, 4) conduct supplementary 
studies focused on pediatric populations to optimize treatment guidelines for this age group 
given their higher risk of failure, and 5) compare age-wise dosing with weight-based dosing, 
or evaluate increased blister pack doses based on higher average body weights. Endemic 
countries can design strategies to systematically monitor the changing threat of antimalarial 
drug resistance.  
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Figures and Tables 
 
FIGURE B.1. Sentinel sites of the National Antimalarial Drug Resistance Monitoring 
System by year, parasite species, and state (district), India, 2009-2010 
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FIGURE B.2. Patient cohort from the National Antimalarial Drug Resistance Monitoring 
System, India, 2009-2010 
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FIGURE B.3A. Kaplan-Meir survival of crude and PCR-corrected outcomes for P. 
falciparum in patients among eligible patients in studies of the National Antimalarial Drug 
Resistance Monitoring System, India, 2009-2010 
 
 
 
FIGURE B.3B. Kaplan-Meir survival of parasite clearance for P. falciparum and P. vivax by 
24 hour intervals among eligible patients in studies of the National Antimalarial Drug 
Resistance Monitoring System, India, 2009-2010 
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TABLE B.1. Clinical and demographic characteristics of eligible patients in studies of the 
National Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
    P. falciparum 
 
P. vivax 
Characteristic  Value n %   n % 
       Area Central 829 57.0 
 
-- 
 
 
Western 391 26.9 
 
55 26.2 
 
Northeast 234 16.1 
 
-- 
 
 
Southern -- 
  
155 73.8 
       Season Monsoon 415 28.5 
 
115 54.8 
 
Post-monsoon 645 44.4 
 
95 45.2 
 
Winter 394 27.1 
 
-- 
 
       Sex Male  835 57.4 
 
172 81.9 
 
Female 619 42.6 
 
38 18.1 
       Age  <1 2 0.1 
 
-- 
 (years) 1-4 120 8.3 
 
2 1.0 
 
5-9 290 19.9 
 
14 6.7 
 
10-14 252 17.3 
 
18 8.6 
 
15-49 689 47.5 
 
154 73.3 
 
≥50 101 7.0 
 
22 10.5 
       Parasite count <1,000 14 1.0 
 
10 4.8 
(/ μL) 1,000-5,000 548 37.7 
 
69 32.9 
 
5,000-10,000 251 17.3 
 
42 20.0 
 
10,000-50,000 526 36.2 
 
83 39.5 
 
≥50,000 115 7.9 
 
6 2.9 
       Febrile  No 451 31.0 
 
63 30.1 
(≥37.5°C) Yes 1,003 69.0 
 
146 69.0 
       History of fever No 31 2.1 
 
4 1.9 
 
Yes 1,423 97.9 
 
206 98.1 
Previous  
      antimalarial  No 1,428 98.2 
 
207 98.2 
drug intake* Yes 9 0.6 
 
0 0.0 
  Unknown 17 1.2   3 1.4 
 
*missing from one site (n=25) 
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TABLE B.2. Primary and secondary outcomes over 28 days of follow-up among eligible 
patients in studies of the National Antimalarial Drug Resistance Monitoring System, India, 
2009-2010 
 
 
    P. falciparum   P. vivax 
  Outcome n %   n % 
Primary  
Adequate clinical and 
parasitological response 1,367 94.0 
 
185 88.1 
classification Early treatment failure 3 0.2 
 
0 0.0 
 
Late clinical failure 7 0.5 
 
0 0.0 
 
Late parasitological failure 17 1.2 
 
0 0.0 
 
Lost to follow-up 33 2.3 
 
12 5.7 
 
Withdrawal after day 0 27 1.9 
 
13 6.2 
       PCR-corrected  Recrudescent 17 63.0 
 
-- 
 results Reinfection 2 7.4 
 
-- 
 
 
Other species 7 25.9 
 
-- 
 
 
Unknown 1 3.7 
 
-- 
 
       Parasite  ≤ 24 hrs 873 61.6 
 
20 10.4 
clearance   24 - 48 hrs 384 27.1 
 
88 45.8 
 
48 - 72 hrs 154 10.9 
 
78 40.6 
  > 72 hrs 6 0.4   6 3.1 
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TABLE B.2S. Risk of P. falciparum treatment failure among patients in studies of the 
National Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
 
Predictor Value Fail ACPR Risk RR 95%CI 
       Area Central 10 786 0.013 -- 
 
 
Western 5 362 0.014 1.07 0.39, 2.93 
 
Northeast 2 229 0.009 0.52 0.07, 4.03 
       Age < 5 5 112 0.043 4.62 1.49, 14.3 
 (years) 5 - 15 5 514 0.010 1.04 0.33, 3.26 
 
≥ 15 7 749 0.009 -- 
 
       Parasite count  <5000 9 532 0.017 -- 
  (/ μL) 5000 - 50000 7 737 0.009 0.57 0.21, 1.51 
 
≥ 50000 1 108 0.009 0.55 0.07, 4.31 
       #Antifolate Wild 0 26 0.000 
  mutations 1-2 16 267 0.057 
  
 
3-4 0 17 0.000 
  
       Fever Yes 14 955 0.014 2.05 0.59, 7.09 
(≥37.5°C) No 3 422 0.007 -- 
 
       Previous  Yes / unknown 0 23 0.000 
  drug intake No 17 1329 0.013 
  
       Artesunate ≥ 3.5 mg 11 1130 0.010 -- 
 underdosing 3-3.5mg 3 112 0.026 2.71 0.77, 9.56 
 
<3mg 2 23 0.080 8.30 1.94, 35.5 
              
 
*per protocol       
  
 
#dhfr+dhps 
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TABLE B.3. Multivariate predictors of P. falciparum PCR-corrected treatment failure 
among patients in studies of the National Antimalarial Drug Resistance Monitoring System, 
India, 2009-2010 
 
 
    Therapeutic efficacy 
Predictor Value RR 95%CI 
Artesunate dose ≥3.5 -- 
 (mg/kg) 3-3.5 2.45 0.58, 10.3 
 
<3.0 6.10 1.04, 35.8 
    Age <5 4.46 1.35, 14.7 
(years) ≥5 -- 
 
    Parasite count ≥5000 0.47 0.22, 1.00 
 (/μL) <5000 -- 
 
    Febrile Yes 3.94 1.40, 11.1 
  No --   
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TABLE B.1S. Site-wise results of therapeutic efficacy and parasite clearance in studies of the National Antimalarial Drug 
Resistance Monitoring System, India, 2009-2010 
 
        Therapeutic Efficacy   PCT (hrs) 
State/UT District/city Drug n ACPR ETF LCF LPF LFU WTH Pv Pf* Surv 95%CI   ≤24 24-48 48-72 ≥72 
Andhra Pradesh Vishakhapatnam ASP 55 52 0 0 0 3 0 0 0 100 -- 
 
46 8 1 0 
Assam Nagaon ASP 51 51 0 0 0 0 0 0 0 100 -- 
 
49 2 0 0 
Chhattisgarh Bilaspur ASP 70 67 0 0 0 2 1 0 0 100 -- 
 
64 5 0 0 
 
Kanker ASP 69 66 0 0 0 3 0 0 0 100 -- 
 
57 11 1 0 
DN Haveli Silvasa ASP 86 78 0 0 1 1 5 1 0 98.8 91.5, 99.8  19 31 29 1 
Goa North Goa CQ 55 52 0 0 0 2 1 0 0 100 -- 
 
7 33 13 0 
Gujarat Surat ASP 82 77 0 3 0 2 0 0 0 96.3 89.0, 98.8 
 
25 35 22 0 
Jharkhand Dumka ASP 56 56 0 0 0 0 0 0 0 100 -- 
 
1 29 26 0 
 
Latehar ASP 72 70 0 0 0 2 0 0 0 100 -- 
 
42 29 0 0 
 
Ranchi ASP 71 69 0 0 0 1 0 0 1 100 -- 
 
68 3 0 0 
 
Simdega ASP 42 39 0 0 0 2 1 0 0 100 -- 
 
1 9 32 0 
Karnataka Gulburga CQ 80 69 0 0 0 10 1 0 0 100 -- 
 
3 25 44 3 
 
Mangalore CQ 75 64 0 0 0 0 11 0 0 100 -- 
 
10 30 21 3 
Madhya Pradesh Betul ASP 75 68 2 0 0 5 0 0 0 97.3 89.6, 99.3 
 
6 42 22 4 
 
Chhindwara ASP 40 39 0 0 1 0 0 0 0 97.5 83.6, 99.6 
 
18 15 7 0 
Maharashtra Gadcharoli ASP 82 75 0 1 4 1 1 0 0 93.8 85.6, 97.4 
 
53 25 2 0 
 
Mumbai ASP 87 86 0 0 1 0 0 0 0 98.9 92.1, 99.8 
 
55 31 1 0 
Meghalaya West Garo Hills ASP 25 25 0 0 0 0 0 0 0 100 -- 
 
21 4 0 0 
Orissa Angul ASP 65 56 1 0 0 4 0 3 1 98.4 88.9, 99.8 
 
55 5 0 1 
 
Dhenkanal ASP 64 56 0 0 1 3 1 3 0 98.3 88.8, 99.8 
 
41 16 3 0 
 
Sambalpur ASP 68 65 0 0 0 0 3 0 0 100 -- 
 
35 29 1 0 
Rajasthan Baran ASP 67 60 0 0 0 1 6 0 0 100 -- 
 
46 16 0 0 
 
Pratapgarh ASP 69 60 0 0 0 0 9 0 0 100 -- 
 
46 13 1 0 
West Bengal Jalpaiguri ASP 80 75 0 0 1 3 0 0 **1 98.7 91.3, 99.8 
 
65 12 3 0 
  Kolkata ASP 78 77 0 1 0 0 0 0 0 98.7 91.3, 99.8   60 14 3 0 
*PF-reinfection, **untypeable
1
1
3
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TABLE B.3S. Molecular markers of anti-folate resistance in P. falciparum isolates collected 
through the National Antimalarial Drug Resistance Monitoring System, India, 2009-2010 
 
 dhfr  dhps 
Result n Haplotype   n Haplotype 
Quadruple  1 S108N/C59R/N51I/I164L    
Triple 6 S108N/C59R/N51I/I164L    
Triple 4 S108N/C59R/N51I/I164L    
Double 235 S108N/C59R/N51I/I164L    
Double 1 S108N/C59R/N51I/I164L  1 S436F/A437G/K540E 
Single 61 S108N/C59R/N51I/I164L  4 S436F/A437G/K540E 
Single 7 S108N/C59R/N51I/I164L  1 S436F/A437G/K540E 
Wild 27 S108N/C59R/N51I/I164L  255 S436F/A437G/K540E 
*Mutations in bold 
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Abstract 
Background 
After the launch of the National Malaria Control Programme in 1953 shortly after 
independence, reported malaria cases in India fell to an all-time low of 0.1 million in 1965. 
However, the initial success could not be maintained and a resurgence of malaria began in 
the late 1960s. Chloroquine resistance in Plasmodium falciparum was first reported in 1973 
and increases in antimalarial resistance, along with rapid urbanization and labour migration, 
complicated the challenge that India‟s large geographic area and population size already pose 
for malaria control. Although several institutions have conducted drug resistance monitoring 
in India, a complete analysis of countrywide data across institutions has been lacking.  
Objective 
We undertook a systematic review of falciparum malaria drug efficacy studies in 
India to summarize drug resistance data and describe changes over the past thirty years in 
order to inform future policy.  
Methods 
We searched Medline and retrieved unpublished studies from the antimalarial drug 
resistance unit of the National Vector Borne Disease Control Programme for chloroquine and 
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sulfadoxine-pyrimethamine (SP) efficacy data from 1978–2007. Only studies with at least 30 
patients completing a minimum follow-up of seven days and treated with the correct dose 
over a standard duration (25mg/kg over three days and 25/1.25mg/kg stat respectively) were 
included. Treatment failure by drug was compared by region, year, and follow-up length of 
each study.  
Results 
We identified 363 in vivo efficacy studies involving 18,620 patients. The median 
proportion of chloroquine failure in a 28-day follow-up was 35% (25–75th percentile: 13–58) 
and the proportion of studies with chloroquine failures exceeding 10% rose from 12% (2/17) 
in 1978–79 to 88% (35/40) in 2006–07 (p<0.0001). The median proportion of SP failure was 
15% (25–75th percentile: 1–33) and SP resistance increased from 8% in 1984–96 to 26% in 
1997–07 (p<0.0001), largely in the Northeast. The extent and rate of chloroquine resistance 
varied by region and, along with resistance to SP, was greatest in Arunachal Pradesh near the 
Burmese border. 
Conclusions 
The results indicate the continued use of chloroquine for the treatment of P. 
falciparum malaria in India would be ineffective. Resistance to SP should be closely 
followed to protect the efficacy of artesunate+SP, which is the new first-line treatment for 
falciparum malaria. Strategies to reduce the emergence and spread of future drug resistance 
need to be pro-active and supported by intensive monitoring. 
 
Introduction 
The Republic of India represents the largest population at risk for malaria in the world 
with 85% of the populace residing in malarious zones (85). Both major Plasmodium species, 
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six primary malaria vectors, several ecotypes including urban malaria, and transmission 
intensities ranging from unstable to hyper endemic highlight the challenging malaria 
epidemiology in the nation. At the time of independence in 1947, the Indian people were 
suffering from an estimated 75 million cases and 800,000 deaths per year (87). 
 
After 
independence health care was prioritized and the control of malaria was one of their key 
aims. In 1953, the National Malaria Control Programme was launched and protected a 
population of approximately 165 million with DDT spraying (82,161).The control 
programme evolved into the National Malaria Eradication Programme in 1958.  Reliable 
surveillance gradually developed during the eradication period and the programme seemed to 
be highly effective with only 99,667 malaria cases and zero deaths reported in 1965. 
However, the long-term success of malaria control could not be sustained. Increasing 
insecticide resistance in mosquitoes, urbanization, development projects, population 
migration, integration with the general health services, financial difficulties and other 
operational challenges laid the foundation for a resurgence of malaria. In 1976, malaria cases 
reached a post-eradication peak of 6.47 million cases (88). A new strategy, the Modified Plan 
of Operation, was introduced in 1977 after which there has been a steady decline in malaria 
cases in the country with only 1.4 million reported cases in 2007. However, the decline in 
malaria was not equal in both P. vivax and P. falciparum species. Around this period, the 
proportion of P. falciparum cases began to increase and comprised 49% of the total burden in 
2007, up from 13% in 1978 even while the rate decreased from 0.90 to 0.67 cases per 1000 
during the same interval (figure 1 – National Vector Borne Disease Control Programme 
data). The changing species dynamics is a cause for concern as P. falciparum is associated 
with higher mortality and rapid development of resistance to new drugs. Increasing drug 
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resistance in P. falciparum is thought to be among the causes for the changing scenario in 
India (162). 
Sehgal et al. first documented chloroquine resistant P. falciparum in the Northeast in 
Karbi-Anglong district of Assam in 1973 (163). Routine monitoring of antimalarial 
resistance using in vivo efficacy trials was initiated in 1978 using 13 regionally-based drug 
resistance teams. While several drug resistance monitoring protocols have been used in the 
past three decades, the test system generally involves the inclusion of patients with defined 
criteria, supervised treatment and follow up for clinical and parasitological outcomes. The 
first reports of sulfa-pyrimethamine (SP) resistance emerged, again from Karbi-Anglong in 
Assam in 1979 (164). A national antimalarial policy was introduced in 1982 to improve 
malaria case management and established SP as the treatment for chloroquine resistant areas. 
Drug efficacy monitoring by the national programme and others has provided data to guide 
treatment strategy and update policy. Artesunate+sulfadoxine-pyrimethamine replaced SP as 
the second-line drug in 2005 for use in treatment failures and as the primary antimalarial in 
areas with documented drug resistance. In 2007, artesunate+SP was selected to be deployed 
as the first-line therapy in high risk districts in addition to identified resistant areas, with the 
goal of covering most of the nation‟s P. falciparum burden, and in 2010 became the universal 
first-line therapy.
 
                     
The public health system responds to antimalarial failures with evidence-based 
policy; however, variations in resistance within the country and a diverse malaria situation 
complicate decision-making. Furthermore, drug resistance studies have been conducted by 
various institutions and a complete analysis of Indian data across institutions is lacking. A 
systematic review was undertaken to (i) summarize antimalarial drug resistance data; (ii) 
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describe temporal and spatial trends which can inform future policy; and  (iii) identify gaps 
in understanding.  
 
Methods 
Search and selection 
We focused our search on the drugs chloroquine and SP and on P. falciparum. Few 
efficacy trials exist for other antimalarial compounds in India and none in regards to routine 
monitoring. Resistance to mefloquine and quinine is reported but appears to be rare (165) and 
the cases are not well documented. Trials using artemisinin combination therapies in India 
have consistently demonstrated treatment success above 95% (166,167).With regards to 
vivax malaria, only a few case reports of chloroquine resistance (namely Mumbai, Uttar 
Pradesh, and Bihar) exist. Contrary to these reports, systematic trials from across the country 
have reported 100% efficacy of the standard dose of chloroquine (25mg/kg over three days) 
(168).
  
At present, chloroquine resistant P. vivax is not a major concern for India. 
We reviewed data collected between 1978 and 2007 (the year drug policy changed) 
from published and unpublished sources. First, we searched the PubMed/Medline database 
through June 1, 2008 with the following terms: (“India”) AND (“malaria” OR “falciparum” 
OR “Plasmodium falciparum”) AND (“resistance” OR “resistant” OR “failure” OR 
“efficacy” OR “sensitivity”). There were no language restrictions to the search. Second, we 
retrieved unpublished data from the National Vector-Borne Disease Control Programme, 
National Institute of Malaria Research, and the World Health Organization headquarters as 
well as its Southeast Asia Regional Office. We examined the abstracts (or titles if the 
abstracts were unavailable) to identify published articles that mentioned any type of P. 
falciparum resistance (in vivo, in vitro, molecular) to chloroquine or SP. Next, we undertook 
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a detailed manual review and excluded articles or unpublished studies that (1) did not 
describe a minimum of seven days of follow-up for chloroquine and 28 days for SP (2) did 
not use standard dosing, i.e. 25mg/kg over three days for chloroquine, or 25/1.25mg/kg as a 
single dose for sulfa-pyrimethamine (3) had less than 30 patients complete follow-up (4) 
included patients with severe malaria (5) included recrudescent patients (6) did not provide 
exact or graphical data regarding the number of patients who completed follow-up and 
number of treatment failures (7) could not geographically disaggregate results to at least the 
district level.  
 
Data extraction 
Two investigators searched for and recorded the total number of studies. One 
investigator merged the datasets and extracted the following information for each study:  
study year, administrative divisions (state, district), number of patients, total number of 
failures, duration of follow-up, and PCR correction if any. For studies spanning more than 
one year, the start year of the study was recorded. The smallest unit of geography recorded 
was the district (second level administrative unit after the state level, with approximately 1 to 
3.5 million population). In terms of healthcare provision the district is the smallest unit at 
which at least a public secondary care facility is available. Studies spanning multiple areas of 
the same district but in the same year and by the same investigator were aggregated. Each 
study was assigned a geographic region based on states: East (Andaman & Nicobar Islands, 
Bihar, Chhattisgarh, Jharkhand, Orissa, West Bengal), North-central (Haryana, Madhya 
Pradesh, Uttar Pradesh), Northeast (Arunachal Pradesh, Assam, Meghalaya, Mizoram, 
Nagaland, Tripura), South (Andhra Pradesh, Karnataka, Tamil Nadu) and West (D & N 
Haveli, Goa, Gujarat, Maharashtra, Rajasthan).  
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Drug resistance monitoring 
Since 2005 the policy on the cut off needed for the routine use of second-line malaria 
treatment in an area has been more than 10% total treatment failure in that locale in a sample 
of minimum 50 patients.
14
 Before adopting this threshold, routine drug efficacy monitoring 
was conducted according to in vivo protocols of the World Health Organization. However, 
most 7-day trials were conducted according to the method of Prasad et al. (169) and the cut 
off point for treatment change was 25% RII+RIII resistance in a minimum of 30 patients, 
which is comparable to early failures according to new protocols. Currently, the WHO 
standard therapeutic efficacy test provides the information for deciding the change of 
treatment policy. The duration of follow up is determined by half-life of the drug being tested 
but was 28 days for chloroquine and SP studies conducted through routine monitoring. The 
classification of therapeutic response varied from study to study with most using the 
prevailing WHO criteria of their time. Presently, outcomes are classified as early and late 
treatment failures or adequate response according to the most recent guidelines (117). For our 
purposes we used a composite definition of treatment failure which included the classical RI, 
II, III criteria
 
and the revised WHO criteria of 1996 which forms the basis of current 
standards.
 
For 28 day follow-up studies this covers recrudescence after clearance of 
parasitemia (RI, late treatment failure), reduction in parasitemia by >75% of baseline without 
clearance (RII, early treatment failure), failure to reduce parasitemia to <25% of baseline 
(RIII, early treatment failure), and fever or signs of severe malaria. The follow-up day at 
which each criteria was assessed varied between the classical, which collected daily blood 
smears up to day 7, versus the revised protocol, which does not. We used the outcome 
designated at the time of the study since detailed data on individual patients was not available 
precluding the possibility of reclassification. 
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Analysis 
The proportion of treatment failures was calculated per protocol for each study. The 
total number of treatment failures (uncorrected by PCR) was divided by the number of 
patients excluding those lost to follow-up. We analysed the proportion of treatment failures 
by study state, region, decade, and follow-up period. We examined the change in chloroquine 
resistance by plotting the proportion of failures in each 28 day study by the study year. Since 
the present strategy is to change policy at more than 10% level, the comparison of the 
proportion of 28 day studies exceeding a certain proportion of failures by year was done 
using this cut off. We used Fisher‟s exact test to analyse the change in the proportion of 
studies exceeding the 10% treatment failure cut-off from when routine monitoring began to 
the end of the study period. The change in the proportion of SP failures was calculated using 
the chi-square test. To determine differences in chloroquine treatment failure proportions 
between regions we performed a Kruskal-Wallis nonparametric test for K independent 
samples using SPSS version 14.0. The study periods for comparison were determined by 
observing the slope of change in the proportion of treatment failures. To produce a national 
map of existing resistance, we identified districts where a study exceeded 10% treatment 
failure in any length of follow-up. If a high proportion of failures occur in a short study, even 
more failures would be expected in a longer follow-up period. Districts endemic for P. 
falciparum were identified by examining surveillance data and selecting areas reporting an 
annual incidence >1 per 100,000 population. Maps were produced using Health Mapper 
software (Version 4.2, World Health Organization, Geneva).  
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Results 
The literature search of the PubMed/Medline database produced 738 articles of which 
649 were not eligible for detailed review (figure 2). The abstracts of ineligible articles 
addressed various topics including P. vivax malaria, experimental compounds, insecticide 
resistance, etc and therefore did not pertain to the topic of interest. Of the 89 articles 
manually reviewed, 41 were included in the review. Some articles reported the results of 
multiple studies (i.e. in vivo trials conducted in different districts). We also collected 334 
unpublished studies of which 315 were included in the analysis. Among both published and 
unpublished sources, not all studies reported the number lost to follow-up. Some studies 
included single-dose primaquine (0.75 mg/kg) for gametocytocidal effect as per national 
policy. PCR-corrected results were available for three studies (but were not used in our 
analysis). In these studies, the proportion of treatment failures classified as reinfections 
ranged from 0 to 8%, but not all samples were successfully genotyped. As malaria 
transmission in most of India is low, we expect low rates of reinfection.  More studies have 
been undertaken recently with 161 trials since 2000 compared to 121 in the 1990s, 64 in the 
1980s, and 18 in the late 1970s. 134 studies were conducted in the eastern region, 72 in the 
northeast, 64 in the west, 60 in the south, and 34 in the northcentral area. There were 119, 4, 
and 240 studies with 7, 14, and 28 days of follow-up respectively.  
  
Chloroquine resistance 
337 studies of chloroquine efficacy with 17,189 patients were recorded. The number 
of studies and proportion of failures varied between regions and in states within a region 
(table 1). The median proportion of chloroquine failure was 35.1% (25–75th percentile: 13.0–
58.2) in studies with a 28 day follow-up period. Studies with 7-day follow up, which largely 
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detected early treatment failures, were phased out beginning in 2000 and the last seven day 
study was conducted in 2003. The proportion of failures detected is higher in 28 day follow-
up studies than in 7 day follow-up studies conducted in the same areas since late treatment 
failures are detected in the former.  
Studies conducted between 1978 and 2007 show a trend of an increasing proportion 
of failures to chloroquine over time (slope=0.73, r
2
=0.07) (figure 3). When routine 
monitoring of drug resistance began in 1978-79, 2 out of 17 studies, 12%, exceeded the 10% 
threshold currently used in India to switch an area to the second-line treatment. In 2006-07, 
the proportion of chloroquine studies exceeding 10% treatment failure increased to 88% (35 
out of 40 studies, p<0.0001) (figure 4). 
 
Regional variation in chloroquine resistance  
Drug efficacy studies of chloroquine, with a minimum of 30 patients in any period of 
follow-up, have exceeded 10% treatment failure in 115 districts (figure 5). These districts 
represent 20 out of 28 states and 2 of 5 union territories. The remaining states and territories 
either have little P. falciparum and/or have not undertaken any trial of antimalarial drug 
resistance. There were eight districts in which all drug efficacy studies conducted did not 
have more than 10% treatment failure. However, only three of the studies were conducted 
since 2000 and there may be subsequent changes in parasite drug sensitivity since the study 
was performed. From 1978-1985, the median proportion of treatment failure between regions 
(Northeast > East > West > South > Northcentral) were significantly different (χ2=20.45, 
p=0.001).  For the data from 1986–2007, there is a similar trend but the difference was not 
statistically significant (χ2=8.91, p=0.06) as the median proportion of treatment failures 
increased substantially in all regions.  
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Sulfa-pyrimethamine resistance 
Between 1978 and 2007, 26 studies of SP efficacy with 1431 patients of SP were 
conducted. Three studies, all in Assam, used sulfalene (Karbi-Anglong 1984, Nalbari 1992, 
Darrang 1993), while the rest used sulfadoxine. The median proportion of SP failure was 
15.0% (25–75th percentile: 0.7–33.1) in 28 days of follow-up. SP resistance increased from 
7.7% (19/246) in 1984–96 to 25.9% (307/1185) in 1997-07 (χ2=38.29, p<0.0001) (table 2). 
Most of the studies were conducted in northeastern states and Arunachal Pradesh, which is 
along the Chinese and Burmese borders, displayed the highest SP failure rate.  
 
Discussion 
Efficacy studies on antimalarial drugs conducted in India since 1978 indicate that P. 
falciparum resistance to chloroquine increased over time and is present across all regions of 
the country. The efficacy of sulfa-pyrimethamine for P. falciparum was reduced in some 
recent studies, largely in the Northeast. 
 
Chloroquine resistance: changes over time 
Nationally, treatment failures of chloroquine increased between 1978 and 2007. 
However, the drug resistance monitoring programme was designed to aid in the detection of 
“foci” of antimalarial drug resistance for the change of treatment policy. Longitudinal trends 
were only obtained in a few areas. Study sites were purposively sampled using a number of 
criteria: clinical case reports, outbreak prone areas, high P. falciparum burden, development 
project areas, reported malaria fatalities, etc. Thus, in each year there was broad variation in 
treatment failure as studies were conducted in diverse settings across the sub-continent. The 
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heterogeneity in the location of and frequency of studies created challenges in aggregating 
data and drawing broader conclusions. Yet, we observed an increase in the proportion of 
failures over time. This trend persisted with the inclusion of 7-day follow-up studies, in 
which we found the mean proportion of failures was lower due to a shorter follow-up where 
late treatment failures were not detected.  The proportion of studies exceeding a pre-defined 
threshold of treatment failures also increased over time. Before 2005, 25% treatment failures 
in a study dictated the need to change the first-line malaria treatment for an area. A 10% 
threshold was adopted in line with WHO recommendations and it was demonstrated as a 
cost-effective cut off in India (170).
 
In 2006–07, 88% of trials conducted exceeded the 10% 
treatment failure threshold necessary for switching an entire area to the second-line drug. 
This suggests further studies of chloroquine resistance, in the few areas remaining to be 
phased into artesunate+SP treatment, will have limited utility as nearly all trials detected 
more than 10% treatment failure. Finally, the increase in chloroquine-resistant P. falciparum 
has contributed to the growing proportion of P. falciparum within total malaria cases (171).
 
Changes in the proportion of P. falciparum could serve as an indicator of the effects of the 
broader use of artesunate+SP which is now deployed in areas covering more than 90% of the 
reported national P. falciparum burden.  
 
Chloroquine resistance: changes over space 
The median proportion of chloroquine resistance initially varied by region. Most 
treatment failures occurred in the Northeast where the original focus of drug resistance was 
found, followed by the eastern and then western regions. Drug resistance in the northeast area 
likely originated from neighbouring countries (Thailand 1962, Myanmar 1969, Bangladesh 
1970) which reported chloroquine failures before India (172,173). Resistant parasite strains 
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may have then spread across India through host movements, particularly the migrant labour 
which travels from eastern India to the western states (174).
 
Thus, chloroquine resistance in 
India is now widely distributed and our data indicates a geographic clustering of resistant 
areas rather than isolated foci. Most places in the nation which have not been identified as 
chloroquine resistant have not had a drug efficacy study conducted there. Changing treatment 
policy to a second-line drug at the level of the primary health centre, block, or cluster of 
blocks has helped India limit malaria mortality and morbidity among those patients who 
receive care at government facilities. However, it does not appear to have stemmed the 
spread of antimalarial drug resistance. In the face of continued selection pressure, drug 
resistance strains will spread. Without major geographic barriers, transportation between 
nearby areas and interactions between catchment populations assures an exchange of vectors 
and parasite strains. Even when drug sensitivity remains, if the area is in proximity to sites 
with drug resistance then strains will intermingle and in the face of continued chloroquine 
use resistant strains will proliferate due to a competitive advantage. On the other hand, 
effective treatments implemented on larger scales can lower malaria transmission and may 
even reduce existing drug resistance as described in other settings (175–177). Thus, 
minimizing uneven drug pressure by deploying an effective drug at a larger geographic unit 
such as the district, or even cluster of districts, is a better strategy to prevent the spread of 
drug resistance. A larger area for treatment policy change will also necessitate fewer efficacy 
studies and reduces operational challenges related to drug supply. 
 
Sulfa-pyrimethamine resistance 
Similar to other control programmes, the dose and choice of sulfa derivative used in 
India evolved over time.
 
Originally, several sulfa derivatives were deployed including 
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sulfalene but these were gradually replaced by sulfadoxine. The two tablet adult dose was 
found to be as efficacious as the three tablet dose in initial trials; however, the latter became 
the standard after some period. The studies we surveyed were conducted with the full dose 
only. Sulfa-pyrimethamine efficacy was reduced in parts of the country, particularly the 
Northeast region. These study results may be a conservative estimate as SP failures can occur 
after 28 days, and a 42-day follow-up is now recommended where possible. Since a more 
widespread use of SP would increase resistance, artesunate+SP replaced the monotherapy as 
combination treatments, particularly artemisinin-based therapies, are touted as a means for 
both the provision of effective treatment and the prevention of drug resistance (135).
 
There is 
a concern that as the partner drug, pre-existing resistance to SP could compromise the 
combination therapy. Additionally, while age group blister packs of artesunate+SP are being 
made available, in principle, a co-formulated drug would be ideal. Although these constraints 
were recognized at the time of the inclusion of artesunate+SP into the national drug policy, 
this was the only option available as co-formulated ACTs were not registered. Treatment 
with artesunate+SP has demonstrated adequate safety and efficacy till date in India and is 
available in sufficient quantities. Recently, trials with several fixed-dose combinations such 
as artesunate-mefloquine, artesunate-amodiaquine, artemether-lumefantrine, dihydromisinin-
piperaquine and artesunate-pyronaridine have been completed to provide local efficacy data 
for other options. Determining and preparing “back-up” combination therapies is high 
priority. In the meantime artesunate+SP efficacy requires careful monitoring.  
 
Limitations of the study 
 Our study has two main limitations. First, a range of quality control issues varied 
between studies or were not reported. These include selection criteria, microscopy technique, 
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drug quality, record keeping, etc. Our results are derived from a per protocol analysis and 
differences in the amount of and reasons for loss to follow-up could impact estimates of 
treatment failure. While exact numbers are not available for most of the studies, in our 
experience loss to follow-up rarely exceeded 10% and in most studies was zero. This is due 
to the mass fever survey approach used for recruitment in many studies. The study team 
enrolls the entire study population at once and then remains in the area until the completion 
of the trial. Second, the variability in the study methodologies is relatively minor compared 
to differences in the number of studies and their location each year. The diverse range of 
years and sites in which studies were conducted make data aggregation difficult. Previously 
discussed operational factors dictated the number and location of studies. Treatment failure is 
an indirect measure of true parasite resistance, as host immunity and pharmacokinetics also 
determine outcomes. Expected variation in the latter factors between different areas of the 
country could be responsible for some of the variation in treatment failure rather than any 
difference in resistance. Caution should be exercised in attempting to interpret any precise 
summary estimate of treatment failure. Thus, we did not produce a meta-analysis but rather 
focused on overall trends through a systematic review. The large number of studies analysed 
should mitigate the limitation posed by the temporal and spatial variability of the data. 
 
Current Indian initiatives against drug resistance  
The National Vector Borne Disease Control Programme has responded to the 
challenge of drug resistance with several strategies. Rational drug use is being promoted in 
order to reduce the overall drug pressure. This involved the phasing out of presumptive 
therapy, strengthening of microscopy services, and extending the availability of rapid 
diagnostic tests to peripheral areas using the nationwide community health worker (ASHA) 
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system under the National Rural Health Mission (178). Second, inadequate dosing or the use 
of improper therapies, such as the use of parenteral artemisinin derivatives for treating 
uncomplicated malaria, can promote resistance. New guidelines have been developed in 
cooperation with the National Institute of Malaria Research which present the treatment 
policy in an accessible format for public and private physicians in order to improve 
compliance. Regulation banning the sale of oral artemisinin monotherapy is in place. A 
group of 15 alternating sentinel sites were selected in 2009 to enable the longitudinal 
monitoring of antimalarial drug resistance. Molecular techniques such as PCR correction of 
treatment failures are now used in antimalarial drug efficacy trials with help of research 
institutions such as the National Institute of Malaria Research.   
 
Future steps 
Further research and programme efforts are needed to combat antimalarial drug 
resistance in India. Previously, with chloroquine treatment the inclusion of primaquine as a 
gametocytocidal agent was standard. Artemisinin combination therapies exhibit useful 
gametocytocidal properties but do not eliminate mature gametocytes. It is not clear whether 
the addition of single-dose primaquine to artesunate+SP will impact malaria transmission or 
the spread of drug resistant strains in India. In vitro susceptibility and molecular markers 
reflect intrinsic resistance to a drug and their changes precede clinical resistance in the field 
(179). Molecular and in vitro monitoring could supplement efficacy trials and provide early 
warning regarding emerging drug resistance.  Finally, the introduction of resistant malaria 
into non-immune populations such as refugees or migrants increases the opportunity for 
manifestation and spread of resistance, because parasites with low or moderate resistance 
would be cleared in semi-immune populations (180). In India, antimalarial resistance for 
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chloroquine and SP was first reported near and exhibits an increasing gradient towards the 
international border with Myanmar (181). Now reports of artemisinin “tolerance” along the 
Thai-Cambodia border and the historical westward spread of drug-resistant strains generate 
concern about the long-term efficacy of artemisinin combination therapies in India (147). 
Best practices for malaria control along border areas and in migrant populations in India need 
to be determined. Overall, a robust and specific plan to combat drug resistant parasites will 
be fundamental in fulfilling our commitment to control malaria in India.  
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FIGURE C.1. The incidence of and proportion of P. falciparum malaria cases in India 
between 1961-2007. Source: NVBDCP 
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FIGURE C.2. Search strategy and selection criteria 
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FIGURE C.3. Chloroquine resistance studies with 28-day follow-up by the proportion of 
treatment failures in India between 1978 and 2007 
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FIGURE C.4. Number of 28-day chloroquine resistance studies in India between 1978 and 
2007 by the proportion of treatment failures exceeding 10% 
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FIGURE C.5. – Districts in India with chloroquine treatment failure >10% (red) in any 
study between 1978 and 2007 and present P. falciparum endemic areas (gray lines) 
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TABLE C.1. Results of chloroquine efficacy studies conducted in India between 1978 and 
2007 by area, year and duration of follow-up 
 
  all follow-up* 
 
7d only 
 
28d only 
  studies n failures % 
 
studies n failures % 
 
studies n failures % 
Region (state) 
              
Northcentral 33 2723 687 25 
 
16 741 116 16 
 
17 1982 571 29 
Haryana 3 113 21 19 
 
1 38 0 0 
 
2 75 21 28 
Madhya Pradesh 17 1922 556 29 
 
12 591 86 15 
 
5 1331 470 35 
Uttar Pradesh 13 688 110 16 
 
3 112 30 27 
 
10 576 80 14 
               
Northeast 54 2541 893 35 
 
13 446 58 13 
 
38 1946 759 39 
Arunachal Pradesh 7 290 174 60 
 
1 30 1 3 
 
6 260 173 67 
Assam 37 1909 607 32 
 
10 356 54 15 
 
24 1404 477 34 
Meghalaya 5 159 20 13 
 
2 60 3 5 
 
3 99 17 17 
Mizoram 1 47 28 60 
      
1 47 28 60 
Nagaland 1 34 10 29 
      
1 34 10 29 
Tripura 3 102 54 53 
      
3 102 54 53 
               
East 126 5830 1471 25 
 
61 2613 299 11 
 
64 3079 1130 37 
A&N 2 115 15 13 
      
2 115 15 13 
Bihar 1 37 0 0 
 
1 37 0 0 
     
Chhatisgarh 12 454 87 19 
 
4 141 9 6 
 
8 313 78 25 
Jharkhand 21 971 212 22 
 
13 588 67 11 
 
8 383 145 38 
Orissa 58 2914 719 25 
 
23 1113 122 11 
 
34 1663 555 33 
West Bengal 32 1339 438 33 
 
20 734 101 14 
 
12 605 337 56 
               
South 60 3124 1007 32 
 
6 277 20 7 
 
54 2847 987 35 
Andhra Pradesh 17 775 95 12 
 
5 236 20 8 
 
12 539 75 14 
Karnataka 39 2184 836 38 
 
1 41 0 0 
 
38 2143 836 39 
Tamil Nadu 4 165 76 46 
      
4 165 76 46 
               
West 64 2971 1074 36 
 
23 1049 198 19 
 
41 1922 876 46 
DN Haveli 3 175 19 11 
 
2 121 12 10 
 
1 54 7 13 
Goa 4 183 96 52 
 
1 34 10 29 
 
3 149 86 58 
Gujarat 29 1297 392 30 
 
13 645 141 22 
 
16 652 251 38 
Maharashtra 9 594 297 50 
 
1 45 2 4 
 
8 549 295 54 
Rajasthan 19 722 270 37 
 
6 204 33 16 
 
13 518 237 46 
               
Year 
              
1978-9 18 783 59 8 
 
1 39 0 0 
 
17 744 59 8 
1980s 63 3900 1292 33 
 
10 466 65 14 
 
53 3434 1227 36 
1990s 114 5265 1190 23 
 
81 3578 475 13 
 
33 1687 715 42 
2000-7 142 7241 2591 36 
 
27 1043 151 14 
 
111 5911 2322 39 
Total 337 17189 5132 30 
 
119 5126 691 13 
 
214 11776 4323 37 
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TABLE C.2. Results of 28-day SP efficacy studies conducted in India between 1978 and 
2007 
 
 
state (district) year n 
total 
failures 
percent 
Arunachal Pradesh         
   Changlang 1992 57 4 7 
   Changlang 1999 43 19 44 
   Changlang 2002 65 35 54 
   Changlang 2006 67 38 57 
   Lohit 2002 70 12 17 
   Lohit 2006 212 81 38 
Assam     
   Darrang 1993 36 0 0 
   Darrang 2004 37 4 11 
   Karbi-Anglong 1984 30 8 27 
   Karbi-Anglong 2001 51 18 35 
   Nagaon 2002 78 0 0 
   Nagaon 2003 32 0 0 
   Nalbari 1992 30 1 3 
   North Lakhimpur 2007 47 6 13 
   Sonitpur 2001 49 21 43 
   Sonitpur  2003 32 0 0 
Madhya Pradesh     
   Mandla 1997 114 42 37 
Orrisa     
   Kandhamal  2004 38 1 3 
   Keonjhar 2002 61 0 0 
   Sundargarh 1991 60 6 10 
West Bengal     
   Bankura  2005 35 6 17 
   Jalpaiguri 1996 33 0 0 
   Jalpaiguri 2001 58 11 19 
   Puruilia  2000 30 7 23 
   Purulia 2003 31 0 0 
Total   1431 326 23 
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APPENDIX D: OTHER PUBLICATIONS 
 
Other Peer-Reviewed Malaria Articles Completed During Doctoral Training, 2009-2012 
 
Published 
 
1. Shah NK. Defining and counting malaria deaths. IJMR. 2012 March 135:270-72 
 
2. Mishra N, Anvikar AR, Shah NK, Kamal VK, Sharma SK, Srivastava HC, Das MK, 
Pradhan K, Kumar H, Gupta YK, Gupta P, Dash AP, Valecha N. Prescription practices 
and availability of artemisinin monotherapy in India: where do we stand? Malar J. 2011 
Dec 13;10:360.  
 
3. Chandra S, Shah NK, Sriganesh V. Cochrane Students Journal Club - a learning resource 
for gathering and appraising evidence: An example of rational use of medicines to 
prevent malaria relapse. Intl Journal of User-Driven Healthcare. 2011 Oct 1(4), 31-41 
 
4. Shah NK, Dhariwal AC, Sonal GS, Gunasekar A, Dye C, Cibulskis R. Malaria-attributed 
death rates in India. Lancet. 2011 Mar 19;377(9770):991 
 
5. Lin JT, Bethell D, Tyner SD, Lon C, Shah NK, et al. Plasmodium falciparum gametocyte 
carriage is associated with subsequent Plasmodium vivax relapse after treatment. PLoS 
One. 2011 Apr 20;6(4):e18716 
 
6. Shah NK. Assessing strategy and equity in the elimination of malaria. PLoS Med. 2010 
Aug 3;7(8):e1000312.  
 
Under consideration 
 
1. Anvikar A, Arora U, Shah NK et al. Antimalarial Drug Policy in India: Past, Present and 
Future. Submitted Indian J of Medical Research 
 
2. Shah NK, Kumar A, Valecha N. India and Global Estimates of Malaria Burden. 
Submitted Lancet 
 
3. Sarkar J, Shah NK, Murhekar MV. Incidence of severe malaria and risk factors for death 
in secondary and tertiary health facilities of Alipurduar, India. Submitted J Vector Borne 
Diseases  
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